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Abstract: PAR1, member of the family of protease-activated receptors, is a GPCR whose activation requires a 
proteolytic cleavage at its extracellular N-terminus to unveil a tethered activating ligand. Although thrombin is the 
main activator of this receptor, diverse other proteases can also activate and disarm PAR1. Besides, tethered 
activating ligand-based peptides (PAR-APs) can also activate the receptor. PAR1 mainly signals via G proteins but, it 
can also signal using β-arrestin pathways and by transactivation of other receptors. This complex PAR1 interactome 
is completed with the receptor desensitization, trafficking, and degradation. PAR1 has shown species-, cellular-, and 
physiological or pathological state-dependent specificity. This review try to give an overview on the complex PAR1 
interactome, its therapeutic impact upon the cardiovascular, immune and nervous systems, inflammation and cancer, 
as well as, on its modulation with agonists and antagonists. 
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1. INTRODUCTION 
The protease-activated receptor PAR1 was 
discovered in 1991 as the receptor responsible of thrombin 
signaling on cells. This receptor was cloned from human 
[1] and hamster [2] cells highly responsive to thrombin, in 
Xenopus oocytes. As other PARs, PAR1 is a member of 
the G-protein coupled receptor (GPCR) class A, which 
contains a central core of seven transmembrane 
hydrophobic helices connected by three extracellular and 
three intracellular loops (Fig. 1). Unlike most GPCRs that 
are reversibly activated by extracellular ligands, PAR 
activation requires a proteolytic cleavage at the N-terminal 
extracellular domain, which unveils the recognition 
sequence, termed “tethered ligand”. This tethered ligand 
remains attached to the receptor and its intramolecular 
binding to the extracellular loops triggers conformational 
changes and signaling. Although thrombin is the main 
physiological regulator of PAR1 activity, numerous other 
proteases also cleave and activate this receptor, such as 
factor Xa (FXa), activated protein C (APC), plasmin, 
granzyme A, kallikrein-related peptidases (KLKs), matrix 
metalloprotease-1 (MMP-1), neutrophil elastase (NE), and 
neutrophil protease-3 (PR3). Not all these proteases cleave 
PAR1 at the same site. Therefore, they can expose a 
variety of tethered ligands that can lead signaling through 
different pathways. PARs not only signal through G-
proteins, they can also transmit signals through beta-
arrestins or by transactivation of other receptors. Finally, 
although there is little knowledge on the desensitization 
and trafficking of PAR1, its irreversible activation 
suggests a signal termination mechanism different from 
that of the classical GPCRs. In summary, as other PARs, 
PAR1 is part of a complex network of protein-protein 
interactions (PPIs) not completely deciphered, which 
needs to be cleared up for the validation of PAR1 as a true 
therapeutic target. Modulators of PAR1 activity are 
essential tools to decoding its complex crosstalk system 
and, although some peptides, peptidomimetics and small 
molecules, agonists and antagonists, some of them in 
clinical trials, are known, their number is very limited and 
little is known about their binding sites. In the last years 
several good reviews have deal with different aspects of 
activation, signaling and therapeutic implications of PAR1 
[3-15]. This work is focused on aspects of PPIs, their 
modulation and therapeutic implications.  
2. PRIMARY STRUCTURE, SPECIES AND 
CELLULAR SPECIFIC EXPRESSION 
Human PAR1 has an extracellular amino terminal 
domain of 102 amino acids, comprising a signal peptide of 
21 residues, followed by a propeptide that includes the 
serine protease cleavage recognition sequence, in the case 
of activation by thrombin up to residue 41 [1]. The 
proteolytic cleavage at this site, unmasks the tethered 
activating ligand (TAL), S
42
FLLRN
47
 for thrombin, which 
interacts intramolecularly with the second extracellular 
loop (ECL2) and with the ligand binding site (LBS, 
L
84
PAFIS
89
), also localized at the N-terminal exodomain 
[16, 17]. This domain also contains a hirudin-like sequence 
within residues 51-63 (K
51
YEPF
55
), which is essential for 
high affinity binding of thrombin. This serine protease is 
an extremely potent agonist of PAR1 (EC50 = 50 pM), 
whose activation is blocked by the thrombin inhibitors 
hirudin and hirugen [1]. Synthetic peptides derived from 
the tethered ligand, named “PAR1-activating peptides” 
(PAR1-APs), can activate the receptor without need of 
proteolytic activation. The pentapeptide SFLLR is the 
minimum sequence for full agonist activity but, in general, 
PAR-APs show much lower potency than thrombin (EC50 
> 1 μM), low PAR selectivity, and their signaling can 
differ from that of the activating protease [5, 6, 18, 19].
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In spite of the high sequence homology, some 
differences across species have been found in the tethered 
ligand domain (SFLLRN human and SFFLRN rodent) 
[20]. These sequence discrepancies determine the affinities 
of their respective APs and, as these are used as receptor 
agonists in pharmacological studies, the affinity 
differences must be considered to choose the appropriate 
AP, depending on the animal species under study. 
Fig. (1). Simplified representation of the PAR1 functional domains, thrombin-mediated activation, and G-protein signaling. 
PARs present also animal species specificity in their 
cellular expression and signaling [10]. For example, 
human platelets express PAR1 and PAR4, which signal 
independently, whereas PAR3 and PAR4 are responsible 
of thrombin signaling in mouse platelets, and guinea-pig 
platelets express PAR1, PAR3, and PAR4. Noteworthy, 
key species of trial animals, such as mice, rats, and dogs, 
lack PAR1 on their platelets [21]. This species specificity 
complicates the development of modulators, as their in 
vivo studies must be realized in primates. 
In mouse endothelial cells thrombin activates PAR1 
and PAR4 [22]. However, human endothelial cells, not 
express PAR4. Depending on the type of blood vessel and 
animal species, different physiological and pathological 
effects of PAR1 activation have been reported [9, 23]. The 
PAR profile in vascular smooth muscle cells and 
fibroblasts indicates that PAR1 is the main thrombin 
responsive receptor and PAR3 and PAR4 are not 
expressed in these cells [20]. PAR1 expression in normal 
vascular smooth muscle cells is limited, but it is 
considerably increased in cells localized in vascular 
lesions [10].  Thrombin and PAR1 agonist peptides have 
shown both vasodilating and vasoconstricting activity 
depending on the species and the experimental conditions 
employed. 
PAR1 is also expressed in neurons and astrocytes in 
the central nervous system (CNS), and in neurons of the 
peripheral nervous system, where they have important 
regulatory roles both in normal and disease states [5, 6, 13, 
14]. In normal brain, thrombin is involved in the synaptic 
organization and plasticity, while in neurodegenerative 
disorders it has dual opposite effects [24, 25]. Thus, low 
concentrations of thrombin rescue neural cells from death 
after brain damage, whereas at high concentrations 
augments the brain damage. These dual effects are 
mediated by PAR1 activation. 
Additionally, PAR1 is present in diverse 
inflammatory and immune cells, where it seems to play 
important roles regulating immune responses and 
inflammatory processes [19]. PAR1 is expressed in mast 
cells, monocytes, macrophages, T cells, and natural killer 
cells, but not in neutrophils [7].  
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3. PAR1 ACTIVATION, EXTRACELLULAR 
PROTEIN-PROTEIN INTERACTIONS
Although many proteases have been found to cleave 
and activate PARs in cultured cells (Table 1), the capacity 
of a protease to signal via PARs in intact tissues depends 
on many factors [6]. Proteases must be generated or 
released in the appropriate concentration to activate PARs. 
Although low concentrations of proteases could cleave 
PARs on the cell surface, it is the rate of hydrolysis which 
determines the magnitude of the signal [26]. Hydrolysis 
and activation of PARs may require the presence of 
cofactors. For example, the binding of α-thrombin to the 
glycoprotein Iβα, a cell-surface platelet protein, accelerates 
the cleavage and activation of PAR1 [27]. The capacity of 
a protease to signal will depend on the availability of 
endogenous protease inhibitors which regulate the effects 
of many proteases in vivo. Although many proteases 
capable of activating PARs have been identified in 
cultured cells, the contribution of these activations to 
physiological and pathological processes is unknown. 
Thrombin is the major physiological regulator of 
PAR1, which unveils the tethered ligand S
42
FLLRN
47
, by 
cleaving the N-terminal domain of PAR1 at the R
41
-S
42
peptide bond. However, other coagulation enzymes can 
also activate this receptor. Thus, during coagulation, factor 
VIIa (FVIIa) binds tissue factor (TF), and the complex TF-
FVIIa signals, in part, through PAR1 and PAR2 [28, 29]. 
Although FVIIa, even at high concentrations, does not 
activate PAR1 or PAR2 expressed in Xenopus oocytes, 
when these receptors are coexpressed together with  TF, 
FVIIa efficiently activates PAR2 and, to a lesser degree, 
PAR1. Similarly, soluble factor Xa (FXa) weakly activates 
PAR1, PAR2, and PAR4, but when it is associated in the 
complex TF-FVIIa-FXa potently activates PAR1 and 
PAR2 [28, 30-32]. The receptor responsible of FXa 
signaling depends on the cell and its cofactor expression. 
In endothelial cells and human vascular smooth muscle 
cells, this signaling is mainly due to PAR2 [33, 34], while 
in lung fibroblasts [35] and human atrial tissue slices [36], 
FXa mainly signals via PAR1. These FVIIa and FXa 
signaling mechanisms may have particular importance 
during septic shock, when expression of TF is upregulated 
on several cell types [6]. 
The anticoagulant activated protein C (APC) also 
induces cellular responses through the activation of PAR1 
[37]. Low levels of thrombin are usually present in the 
blood and they participate in the anticoagulant APC 
process when vessels remain intact. Under these 
circumstances, thrombomodulin binds thrombin to the 
endothelial cell surface, where thrombin transforms 
protein C, bound to the endothelial protein C receptor 
(EPCR), into APC. Then, APC is released from the EPCR 
and, as a circulating anticoagulant protein, degrades FVa 
and FVIIa. However, when retained at the cell surface, the 
EPCR-APC complex induces activation of PAR1 [38]. 
This APC-induced PAR1 activation mediates, in large 
part, the anti-inflammatory and neuroprotective effects of 
APC [39]. Studies analyzing the hydrolysis of synthetic 
peptides corresponding to the N-terminal exodomain of 
PAR1 have demonstrated that APC hydrolyses PAR1 at 
the same position that thrombin (R
41
-S
42
). However, the 
activation of this receptor on the endothelial cell surface 
by the APC-EPCR complex is 100-1000-fold less efficient 
than by thrombin and dependent on the expression level of 
EPCR [37]. By contrast, as the half live of thrombin is 
estimated to be only a few seconds and the half live of 
APC is significantly longer (~10-30 min), the APC 
concentration relative to thrombin may be high enough to 
allow significant activation of PAR1 by APC. This 
protease concentration influence could explain some 
responses of PAR1, dependent on the kinetics of its 
activation [38]. Recent studies have also shown that, 
whereas thrombin activation of PAR1 causes endothelial 
disruptive, pro-inflammatory effects, mediated through G-
protein signaling, APC exerts endothelial cytoprotective 
actions via PAR1 activation, through β-arrestin 2 signaling 
[40]. This activation is mediated by the “noncanonical” 
cleavage of the N-terminal domain at the R
46
-N
47
 peptide 
bond [40, 41], with a different tethered ligand to that of the 
unveiled by thrombin. A synthetic peptide comprising 
PAR1 residues 47-66, named TR47, stimulated the 
protective signaling in endothelial cells, as reflected in Akt 
and GSK 3β phosphorylation and endothelial barrier 
stabilization [40]. In mice, TR47 reduced vascular 
endothelial growth factor (VEGF)-induced vascular 
leakage.  
Plasmin can also affect PAR1. The effects are 
complex, since this enzyme can both activate and 
deactivate PAR1 [19]. It has been shown that plasmin can 
both activate and inhibit platelets, depending on its 
concentration. Low concentrations of plasmin inhibit 
platelets by truncating the PAR1 exodomain at the 
R
70
/K
76
/K
82
 sites, inactivating and desensitizing the 
receptor. Whereas higher concentrations of plasmin 
activate PAR1 by the cleavage at the R
41
 site (the same as 
thrombin) [42]. In astrocytes and neuronal cultures 
plasmin activates PAR1, while in CA1 pyramidal neurons 
it potentiates NMDA receptor synaptic currents [43]. 
Amongst the immune cell-derived proteases, 
granzymes A, B, and K induce neurotoxicity via activation 
of PAR1. In neuronal cells and astrocytes, granzyme A 
causes morphological changes, as neurite retraction, 
mediated through activation of PAR1 by cleavage at the 
same site that thrombin [44]. In cultured human neuronal 
cells, gramzyme B induce neurotoxicity by interacting 
with PAR1, followed by increased expression and 
activation of the potassium channel Kv1.3 and Notch-1 
[45]. Granzyme K activates PAR1, inducing fibroblast 
cytokine secretion and proliferation [46].  
Several tumor-derived proteases also activate PAR1, 
such as the kallikrein-related peptidases (KLKs), which 
have received significant attention. Although the targets of  
KLKs are not clear, it has been proposed that these serine 
proteases could signal by regulating PAR activity [19]. 
Depending on its concentration, KLK14 could both 
activate (high concentration) and disarm (low 
concentration) PAR1 [19]. Recent data suggest that, by 
activating PARs, tumor-related KLKs, such as KLK4, 
KLK6, and KLK14, may play active roles in setting 
carcinogenesis [47-49].. A question to resolve is whether 
or not the high levels of KLKs in tumor-derived or body 
fluid samples represent enzymatically active species. The 
data suggest that, although the proportion of enzymatically 
active KLKs is low, the amount of active enzyme 
PAR1 Receptor/Protein Interactions 
4 
produced by tumors could be sufficient to participate in the 
regulation of PAR activity [47].  
Matrix metalloproteases MMP-1 and MMP-13, two 
proteases produced in the setting of tumorigenesis also 
regulate PAR activity [50, 51]. These metalloproteases are 
tumor-cell-derived enzymes that can promote the invasive 
activity of cancer cells by PAR1 activation [52-54]. 
Furthermore, these zinc-dependent metalloproteases, 
members of the family of collagenases, are expressed in 
most human tissues, including the majority of cell types in 
the blood vessel wall, inflammatory cells, and platelets. 
Recently, it has been shown that both MMP-1 and MMP-
13 activate PAR1 through cleavage at “noncanonical” sites 
distinct from thrombin. MMP-1 cleaves PAR1 at the D
39
-
P
40
 peptide bond, unmasking a two amino acid longer 
tethered ligand (P
40
RSFLLRN
47
). This cleavage activates a 
biased signaling cascade in human platelets, by 
preferential activation of G12/13 proteins, while thrombin 
preferentially activates Gq [51, 55, 56]. MMP-13 
activates PAR1 through the cleavage of the S
42
-F
43
, 
although there is little knowledge about its signaling 
cascade [57]. 
Table 1. PAR1 activating proteases and their participation in PAR1 inactivation 
Activating protease Cleavage site PAR1-APs PAR1 inactivation
Thrombin R41S42
SFLLRN
TFRRRL [58]
TFLLR-NH2 [59]
YFLLRNP [60]
No
TF/FVIIa R41S42 No
TF/FVIIa/FXa R41S42 No
APC
R41S42
No
R46N47 N47PNDKYEPFWEDEEKNESGL66 a
Plasmin R41S42 SFLLRN
TFRRRL 
TFLLR-NH2
YFLLRNP 
Yes
Granzymes A, B, K R41S42 No
KLK4, KLK6, KLK14 Unknown Unknown Yes
MMP-1 D39P40 P40RSFLLRN47 b No
MMP-13 S42F43 Unknown No
NE L45R46 R46NPNDKYE53 c Yes
PR3 A36T37 T37LDPRSFLLR46 c Yes
Gingipains HRgpA and RgpB Unknown Unknown Unknown
Streptokinase-plasminogen Unknown Unknown Unknown
a Reference [40]. b References [51,55 and 56]. c Reference [61]. 
Recently, it has been described that the neutrophil-
derived proteases neutrophil elastase (NE) and proteinase-
3 (PR3) also trigger signaling through PAR1, but in a 
different manner to thrombin [61]. These serine proteases 
unmask two different “noncanonical” tethered ligands that 
lead to activation of Gi coupled to p42/44 MAPK 
signaling, but not Gq-coupled calcium signaling. Thus, in 
an inflammatory setting, enzymes released by infiltrating 
neutrophils would modulate PAR1 signaling by silencing 
its calcium signaling and activating MAPK pathways. NE 
cleavages the PAR1 exodomain at the L
45
-R
46
 peptide 
bond, while PR3 cleavages the A
36
-T
37
 peptide bond. The 
corresponding activating tethered ligand sequences have 
been identified and each of these sequences appear to be 
capable of triggering distinct subsets of PAR1 signals, 
presumably, by inducing unique conformational changes 
in the receptor [61]. In human kidney glomerular 
endothelial cells, PR3, but not NE, activates PAR1, 
although the precise cleavage site has not been identified 
[62]. Besides, both proteases cleavage and inactivate 
PAR1 in a time- and concentration-dependent manner, 
disarming the receptor.    
Some bacterial proteases can also signal through 
mammalian PARs. Among them, the bacterial arginine-
specific gingipains-R (HRgpA and RgpB), produced by 
Porphyromonas gingivallis, main origin of human 
periodontitis, have been implicated in this disease. It has 
been described that HRgpA and RgpB induce platelet 
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aggregation with a similar potency to thrombin and that 
this effect is mediated by PAR1 and PAR4 [63]. These 
results have revealed a novel mechanism by which bacteria 
influence mammalian cells. This mechanism could explain 
the relation between periodontitis and cardiovascular 
disorders. In human oral epithelial cells, RgpB activates 
both PAR1 and PAR2, induces interleukin-6 secretion [64] 
and upregulates expression of the pro-inflammatory 
cytokines IL-1, IL-1β, IL-6 and TNF- [65]. In human 
gingival fibroblasts Rgps induce the production of 
hepatocyte growth factor (HGF) through activation of 
PAR1 and PAR2 [66]. In human monocytic cells, 
gingipains also trigger the production of pro-inflammatory 
cytokines (IL-8, IL-6, and MCP-1) through activation of 
PAR1, PAR2 and PAR3 [67].   
Finally, it has been reported that platelet activation by 
the bacterial proteins streptokinase-plasminogen involves 
PAR1 activation and antistreptokinase antibodies [68].  
4. PAR1 SIGNALING, INTRACELLULAR 
PROTEIN-PROTEIN INTERACTIONS
In general, PAR signaling activates several complex 
signal pathways for which, presently, there is limited 
information regarding their molecular determinants. First, 
as GPCRs, they signal mainly via G proteins; second, they 
can signal through β-arrestin pathways, as above 
commented for the activation of PAR1 by APC; and third, 
they also signal by transactivation of a variety of receptors 
(Fig. 2) [15]. Due to the complexity of signal transduction 
networks of PAR1, most of their molecular crosstalk 
remains undefined. As an example of this complexity,  a 
recent quantitative phosphoproteomic study of the 
thrombin signaling in human endothelial cells has 
identified 2224 thrombin-regulated phosphorylation sites, 
many of them related to its signaling through PAR1 [69]. 
4.1. Signaling via G proteins 
PAR1 activation induces conformational changes in 
the transmembrane domains, the intracellular loops (i1-i3), 
and in the C-terminal domain, also termed i4. These 
conformational changes favor the interaction of the 
receptor with heterotrimeric G proteins through its 
intracellular loops. In the inactive state, a Gα subunit is 
bound to guanosine diphosphate (GDP) and a Gβγ subunit
complex. Activated GPCRs induce a conformational 
change in the Gαβγ trimeric complex that provokes the 
exchange of GDP for GTP in the Gα subunit. With this 
exchange Gα is released from the complex with Gβγ.
Then, both G protein moieties (Gα-GTP and Gβγ) 
independently interact with downstream signaling 
effectors. It seems that in the PAR1/G protein interaction, 
the N-terminal -helix of the Gα subunit interacts both 
with PAR1 and the Gβ subunit [70].
Although a complete knowledge of the PAR1 G-
protein signaling mechanisms lacks, it seems that they are 
cell-specific and may depend on the PAR1 localization 
within the plasma membrane [71]. Besides, it is known 
that cross-talk between diverse G protein-linked pathways 
exists [72, 73]. PAR1 signals through three of the four Gα
protein subfamilies, Gi/o, Gq, and G12/13.
Coupling to Gαi/o inactivates adenylate cyclase, 
suppressing the formation of c-AMP, and activates 
pertussis toxin (PTX)-sensitive MAPK signaling, resulting 
in the activation of phosphatidylinositol 3-kinase  (PI3K) 
[74] and the phosphorylation of ERK1/2 [71]. These 
signaling pathways have been implicated in PAR1-
mediated platelet activation [4, 71]. A recent study has 
indicated that, in platelets, PAR1-mediated PI3K activation 
induces activation and cytoskeletal translocation of the 
protein kinase CK2, which is associated with activation of 
GPIIb/IIIa and platelet aggregation [75]. Another report 
has shown that PAR1 activates the tumor progression 
locus 2 (Tpl2), a kinase required for downstream 
activation of the MAPKs extracellular kinases ERK1/2. 
This activation is via Gαi2, through the activation of 
phospholipase Cβ3 (PLCβ3), which generates inositol 
triphosphate (IP3) that promotes the release of Ca
2+
 and 
Ca
2+
-dependent cell migration [76].  
The coupling of PAR1 to Gα12 and  Gα13 controls cell 
shape and migration [6]. These G-protein subunits interact 
with Rho guanine-nucleotide exchange factors (GEFs) [18, 
77, 78], allowing Rho-mediated control of cell shape and 
migration, as well as with serum response elements (SRE) 
[79]. In platelets, this Gα12/13 induced activation of Rho-
kinases is involved in thrombin-induced shape changes 
[80, 81], while, in fibroblasts and endothelial cells, it is 
involved in permeability and migration [18, 78, 82, 83]. 
RhoA is involved in the PAR1-mediated reorganization 
and cell growth of cardiomyocytes [84]. PAR1-mediated 
activation of Rho-kinases is also involved in the 
cytoskeleton reorganization, cell migration and invasion in 
tumor cells [77, 85, 86]. PAR1 regulates the activity of 
endothelial nitric oxide synthase (eNOS), by inhibition of 
the enzyme upon activation of the Rho/Rho-kinase 
(ROCK) pathway and activation via Gq/protein kinase C 
(PKC)- [87]. Gα13 has been involved in the PAR1-
induced stabilization of β-catenin and in cancer [88]. 
The main coupling of PAR1 to G-proteins is via Gαq
[6, 18]. This coupling activates phospholipase Cβ (PLCβ)
[89], to generate inositol triphosphate (IP3), which 
produces calcium mobilization, and diacylglycerol (DAG) 
that activates protein kinase C (PKC). This pathway leads 
to activation of calcium- and PKC-regulated kinases, such 
as mitogen-activated protein kinases (MAPKs), and 
phosphatases [90]. Given the important mitogenic role of 
thrombin, there has been considerable interest in PAR1 
coupling to the MAPK cascades [5, 6]. In particular, the 
MAPK ERK1/2 module is important in cell proliferation 
and differentiation. Most information about the regulation 
of this module comes from the study of tyrosine kinase 
receptors, such as the epidermal growth factor receptor 
(EGFR). Activation of this receptor opens the cascade of 
phosphorylation from protein Ras to ERK1/2. This cascade 
can be activated via PKC [91] or by PAR1-induced 
transactivation of EGFR [6, 90, 92-94]. In fibroblasts, 
PAR1 activation induces production of the chemokine 
CCL2 by coupling to Gαq in cooperation with the Rho 
signaling pathways through Gα12/13 [73]. Coupling of 
neuronal PAR1 to Gαq regulates endocannabinoid 2-
arachidonoylglycerol signaling, which activates 
presynaptic CB1 receptors and suppresses transmitter 
release at hippocampal inhibitory synapses [95]. 
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Fig. (2). Simplified scheme of the complex PAR1 interactome. 
Gβγ-Subunits couple PAR1 to many other pathways
[4, 6, 96], including phosphatidylinositol-3-kinase (PI3K), 
lipid-modifying enzymes (PLCβ), G protein receptor 
kinases (GRK), potassium channels (Ki), and non-receptor 
tyrosine kinases (TKs). As already commented, PI3K is 
involved in PAR1-mediated regulation of cytoskeletal 
structure, cell motility, cell survival, and mitogenesis and, 
in some cell types, it acts as an intermediate in the 
activation of ERKs [4, 5, 89, 97].
PAR1-APs have shown different functional 
selectivity in PAR1 activation from thrombin due to biased 
signaling through G-proteins [98]. Thus, thrombin via 
PAR1 induces higher increase in endothelial permeability, 
which reflects Gα12/13 activation, that in Ca2+ mobilization 
through activation of Gαq. The opposite order of activation 
was observed for the PAR1-APs, which favor Gαq
activation [18]. As commented in the previous section, 
different activating endogenous proteases can also activate 
biased signaling cascades by their “non-canonical” 
tethered activating ligands. MMP-1 preferentially activates 
Gα12/13-Rho-dependent pathways, chemotaxis, and MAPK 
signaling [51, 55]. NE and PR3 also with “non-canonical” 
TALs selectively activate PAR1-mediated MAPKs via Gαi
signaling [61]. Selective signaling may also be dependent 
on the receptor location. For example, the endothelial 
barrier protective effects and selective signaling of APC 
are mediated through the compartmentalization of PAR1 
in caveolae [99]. Furthermore, the cytoprotective effects of 
APC are mediated by signaling through β-arrestin 2 via the 
mentioned non-canonical activation of PAR1 [40]. With 
respect to PAR1 antagonists, most of them have been 
investigated based on their pharmacological activity as 
antiaggregant agents and there is scarce information on 
their action upon the PAR1 signaling cascade. However, 
three different families of small-molecule antagonists have 
been reported in the last years that seem to selectively 
inhibit the Gαq-mediated PAR1 signaling [100-102]. 
Very little is known regarding the mechanisms of 
PAR1G-protein signal transference and about the 
structural elements of these macromolecular interactions. 
Several unsolved question have been raised respect to 
these signaling mechanisms. 1) Does PAR1 form 
preassembled complexes with different Gα subunits 
previously to the agonist binding or is the agonist-induced 
activation necessary for the PAR1-G-protein coupling? 
The existence of, at least, two distinct receptor populations 
has been suggested. In one of them PAR1 could 
preassemble Gαi1, and receptor activation would induce 
rapid and transient Gαi1 activation and stable recruitment 
of β-arrestin 1. In the other population, PAR1 would not be 
preassembled and, after ligand binding, Gα12 or β-arrestin 
1 would be recruited to form a complex with the receptor 
and to initiate the signaling cascade. These alternative 
modes of PAR1-G-protein assembly and signaling appear 
to depend on the Gα C-terminus [103]. 2) Does PAR1 
include specific recognition sites for each G-protein or do 
different G-proteins dock at overlapping recognition sites? 
First studies trying to answer this question with 
experiments of chimeric receptors indicated that the 
PAR1 Receptor/Protein Interactions 
7 
second intracellular loop (i2) of PAR1 is involved in its 
coupling to Gαq [104]. Subsequent studies implicated key 
roles for i2, i3, and the C-tail [105]. A more recent study 
has found that the 8
th
 helix region at the PAR1 C-terminus 
is critical for activation of the Gαq-dependent signaling 
branches [106]. Furthermore, a network of H-bond and 
ionic interactions was found to connect the N-terminal 
portion of the 8
th
 helix, through the hydrophilic residues 
E
377
, Q
379
, and R
380
, to the nearby N
367
PLIY
371
 motif in 
transmembrane helix 7 and to the i1 loop. Disruption of 
these interactions cause additive defects in the coupling to 
G-protein. A recent work has identified five amino acids 
within PAR1 i2 loop (R
205
, V
209
, P
212
, I
213
, and L
216
) that 
markedly reduced signaling via Gαq/11 when individually 
mutated. Among these mutations, only R
205
 completely 
abolished the direct binding of Gαq/11 to PAR1. None of 
these mutations affected the direct binding of PAR1 to 
either Gαi/o or Gα12/13 and their respective signaling [107].  
4.2. Signaling via β-arrestins
β-Arrestins (β-arrestin 1 and 2) were originally 
identified as terminators of G-protein coupling and 
mediators of endocytosis, but later, they were shown to 
function as scaffolds linking receptor activation to several 
signaling cascades [108], mainly to MAPK and PI3K 
signaling. A large body of work has demonstrated that 
diverse parameters, such as agonist structure, agonist 
concentration, receptor clustering and prevalence of 
signaling components can switch the receptor signal from 
a G-protein-dependent to a G-independent one. β-Arrestins 
can work both in opposition and in synergy with the G-
protein signaling. In other cases, β-arrestins and G-proteins 
can activate the same downstream protein, but through 
different mechanisms, leading to distinct cellular outcomes 
[109]. The availability of these diverse downstream 
signaling possibilities through specific G-proteins or β-
arrestins is cell-type-specific. Up to now, most of the 
studies on receptor signaling have been based on 
measuring G-protein second messengers. As a 
consequence, other signaling pathways have been 
disregarded, as in the case of PAR1, where there is very 
limited information on the contribution of β-arrestins to its 
signaling cascade. It has been described that β-arrestin 1 
couples PAR1 to the rapid and sustained activation of 
PI3K/Akt signaling pathways that are essential for the cell 
progression through the G1 phase [110, 111]. On the other 
hand, β-arrestin 1 and β-arrestin 2 have shown opposing 
effects on the activation and degradation of Src induced by 
PAR1 [112]. PAR1-mediated activation of Src and 
ERK1/2 was increased with overexpression of β-arrestin 1 
or depletion of β-arrestin 2. This β-arrestin also appears to 
promote the PAR1 induced degradation of Src. Finally, as 
abovementioned, the PAR1-mediated endothelial 
cytoprotective actions of APC are induced through β-
arrestin 2 signaling [40, 113].
4.3. Signaling via receptor transactivation
GPCRs can signal through other receptors by a 
process known as transactivation, which is defined as 
“GPCR activation which leads to the activation of a 
second cell surface receptor in a relatively short time and 
in absence of de novo protein synthesis” [114]. This 
transactivation includes intra- and extra-cellular 
mechanisms and may involve a direct interaction between 
the two receptors, or not. By transactivation PAR1 can 
activate receptor tyrosine kinases (RTKs), receptor 
serine/threonine kinases (RSTKs), other GPCRs, and ion 
channels [15]. Among the transactivation of RTKs, besides 
the transactivation of EGFR, already commented, it has 
been reported that the crosstalk between PAR1 and the 
platelet-derived growth factor receptor (PDGFR) in spinal 
cord neurons is implicated in neuropathic pain after nerve 
injury [115]. It has also been reported the implication of 
PAR1-mediated transactivation of the insulin-like growth 
factor receptor (IGFR) in the regulation of aortic smooth 
muscle cell proliferation [116, 117]. In endothelial cells, 
PAR1 transactivates, in a Src-dependent manner, the RTK 
of ephrin-A1, EphA2 [118]. 
 Recent works suggest that PAR1 can also 
transactivate RSTKs, concretely, the transforming growth 
factor beta (TGF-β) receptor (TβRI), also known as 
activin-like kinase V (ALK V). The thrombin stimulation 
of proteoglycan synthesis in vascular smooth muscle is 
mediated by PAR1 transactivation of TβRI [119]. 
Overstimulation of PAR1-mediated activation of ALK V 
can promote acute lung injury [120]. 
Growing pharmacological and biochemical data 
indicate that most GPCRs, including PARs, form 
functional homo- and heterodimeric complexes. These 
processes increase the diversity of receptor functions and 
lead to synergic signaling. During the past few years 
distinct PAR-PAR interactions, including co- and trans-
activation have been proposed in different cell types. 
However, only limited data exist about homo- and 
heterodimer complex formation and their impact in cells. 
Most of the work has been done with expression systems, 
in which higher than normal receptor concentrations may 
force dimer and oligomer formation not observed in 
naturally occurring cells. Signaling crosstalk between 
endothelial PAR1 and PAR2 in vivo has been 
demonstrated in a sepsis mouse model, where the 
protective effect of PAR1 agonistic activity, mediated by 
APC, on the endothelial barrier and mice survival required 
the presence of PAR2. FRET studies suggested the 
formation of PAR1-PAR2 heterodimers [121]. PAR1 
transactivation of PAR2 has also been demonstrated on 
human umbilical vein endothelial cells (HUVECs) [122]. 
The cooperative signaling between PAR1 and PAR2 
observed on carcinoma cells suggests a role of PAR1-
PAR2 dimerization in carcinogenesis [123-125]. On the 
other hand, the known cooperative participation of the 
PAR1/PAR4 receptor system in human platelet signaling 
and aggregation indicated the possible formation of 
heteromeric complexes. This suggestion has been 
demonstrated in human platelets [126]. The data provided 
evidence for a mechanism by which thrombin first docks 
to and cleaves PAR1, then, reaches over and cleaves PAR4 
while still bound to PAR1. This PAR1-PAR4 interaction 
was further supported by co-immunoprecipitation and 
FRET studies, demonstrating the ability of both receptors 
to form heterodimers in COS-7 fibroblasts transfected with 
PAR1 and PAR4. There are also results suggesting the 
formation of PAR1-PAR4 heterodimers in other cell types, 
including those from epithelial cancers, such as 
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astrocytoma [127] and hepatocellular carcinoma cells 
[128].  
PAR1 can also transactivate non-PAR GPCRs. Thus, 
it seems that the endothelial barrier protection and 
neuroprotective effects of APC are mediated through the 
PAR1 crossactivation of sphingosine 1-phosphate 
receptors (S1PR1 and S1PR3) [129-131]. Also activation of 
neuronal PAR1 transactivates presynaptic cannabinoid 
receptors (CB1), through retrograde signaling mediated by 
2-arachinoylglycerol, and suppresses transmitter release at 
hippocampal synapses [95]. 
Finally, some reports have shown the implication of 
PAR1 activation in ion channel receptor signaling. Thus, 
several lines of evidence indicated that both plasmin and 
thrombin can regulate neuronal functions of NMDA 
receptors through activation of PAR1. Concretely, it has 
been suggested that plasmin regulation of NMDA activity, 
via PAR1, is relevant for synaptic plasticity and behaviour 
[43, 132], while, thrombin/PAR1-induced 
neurodegenerative effects under pathological conditions, 
such as ischemia or hemorrhage, seems to be induced 
through activation of NMDA [133, 134]. In astrocytes 
PAR1 activation can tune synaptic NMDA receptor 
responses by stimulating glutamate release [135].  Also, it 
seems that PAR1 activation can sensitize the transient 
receptor potential ion channel TRPV1 in nociceptive 
neurons [136].
5. PAR1 DESENSITIZATION, TRAFFICKING, 
AND DEGRADATION
Due to its irreversible proteolytic activation, PAR1 
signaling is controlled by rapid desensitization and 
receptor trafficking [6, 10, 13]. The irreversible activation 
suggests that PAR1 might require a signal termination 
mechanism different from that of classical GPCRs. 
Activated and uncleaved PAR1 receptors internalize 
through two different pathways. Protease activation 
induces rapid internalization and degradation of PAR1 in 
an agonist-dependent manner [13, 137]. Internalization is 
preceded by receptor desensitization via rapid GRK-
mediated C-terminal phosphorylation and 
phosphorylation-independent binding of β-arrestins. PAR1 
is mainly phosphorylated by GRK3 and GRK5 on serine 
and threonine residues located at the i3 or the C-terminal 
cytoplasmatic tail [138, 139]. Although internalization of 
PAR1 does not require β-arrestins, receptor desensitization 
is β-arrestin 1 dependent [140], which physically interacts 
with both phosphorylated and unphosphorylated PAR1 
[141]. G-Protein signalling of PAR1 is also regulated by 
regulator of G-protein signalling (RGS) proteins, which 
function as GTPase-activating proteins to inhibit GPCR/G-
protein signaling [142]. It seems that RGS2 and RGS4 
directly interact with PAR1 in a G-dependent manner to 
modulate PAR1/G signaling. It also seems that the 
recruitment of these RGS to the G-proteins is regulated by 
the binding of the clathrin adaptor protein complex-2 (AP-
2) to PAR1 through a C-tail tyrosine-based motif 
(Y
420
KKAA
424
) [143]. 
PAR1 is basally ubiquitinated at highly conserved 
lysine residues localized within the cytoplasmic tail 
tyrosine-based motif of binding AP-2 [144]. This 
ubiquitylation may preclude AP-2 binding. Consequently, 
internalization of PAR1 involves firstly deubiquitylation, 
followed by interaction with AP-2 [144] and epsin 1 [145]. 
These processes result in clathrin- and dynamin-dependent 
endocytosis to early endosomes. The adapter protein 
bicaudal D1 (BicD1) is involved in the transport of PAR1 
from the plasma membrane to endosomes [146]. BicD1, 
through its CC3 domain, directly interacts with the C-
terminal 8
th
 helix of PAR1, inhibiting its signaling to Gq-
PLCβ. Silencing BicD1 expression impairs PAR1 
transport to endosomes and this adapter protein has been 
found to be a potent suppressor of PAR1-driven 
proliferation of breast carcinoma cells [146]. PAR1 is 
translocated from endosomes to lysosomes for degradation 
[147]. This traslocation requires physical interaction with 
sorting nexin 1 (SNX1) [148]. Other endocytic adaptor 
proteins may mediate the sorting of PAR1 to lysosomes, 
but have not been identified yet. 
There is little information on the lysosomal 
degradation of PAR1. A recent report has suggested the 
participation of prohibitin (PHB), a regulatory protein in 
the maintenance of mitochondrial functions, in the 
internalization and degradation of PAR1 [149]. In cancer 
cells, the absence of plasma membrane PHB induces 
persistent PAR1 signaling, while, upregulation of 
intracellular PHB decreases PAR1 degradation, which may 
render cancer cells highly invasive. As already commented 
in section 3, PAR1 can also be disarmed by extracellular 
protease-mediated degradation of the extracellular N-
terminus downstream to the tethered ligand. This is the 
case of the PAR1 inactivation by plasmin [19, 150], KLKs 
[19], neutrophil elastase, proteinase-3 and thermolysin [62, 
151, 152], trypsin  [153], tryptase and chymase [154], and 
cathepsin G [155].  Receptor disarming by trypsin, 
thermolysin, elastase and proteinase-3 is governed by 
PAR1 glycosylation at the N-terminus downstream to the 
tethered ligand, mainly at Asn
75
 [152]. Receptors 
inactivated by extracellular proteases remain at the cell 
surface, but are not longer available for protease-mediated 
activation, although they can be activated by PAR1-APs. 
Uncleaved PAR1 is internalized by constitutive 
clathrin-coated pit, AP-2, and dynamin-dependent 
endocytosis, negatively regulated by ubiquitination. This 
constitutive internalization modulates cell surface 
expression of uncleaved PAR1, which can recycle between 
endosomes and the cell surface and lead to fast
resensitization, independent of de novo receptor synthesis 
[10, 13, 156]. 
6. PAR1 THERAPEUTIC IMPLICATIONS
The complex interactome of PAR1 and its wide 
cellular expression give an idea of the multiple 
physiological functions of this receptor and of the 
pathological implications of its dysfunctions, mainly in the 
cardiovascular [9, 11, 157, 158], immune [7, 159], and 
nervous [24, 25, 160, 161] systems, inflammation [7, 162-
164] and cancer [12, 165, 166], that are summarized in 
Table 2. Many of these pleiotropic actions are PAR1-
mediated in combination with PAR2 or PAR4. 
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6.1. Cardiovascular system
In the cardiovascular system, PAR1 is mainly 
expressed in platelets, endothelial and vascular smooth 
muscle cells. The effects of PAR1 activation are cell type-
dependent and its cellular expression varies from 
physiological to pathological conditions [157]. Depending 
on cell expression, PAR1 activation causes platelet 
activation and aggregation, arterial vasodilation, 
venoconstriction, and release of coagulant and fibrinolytic 
factors [167].  
Human platelets express PAR1 and PAR4, and 
activation of each of them induces platelet secretion and 
aggregation [168]. Both receptors account for most 
thrombin signaling in platelets. PAR1 mediates fast 
platelet responses at low thrombin concentrations, while 
PAR4 mediates slow and prolonged platelet activation at 
high thrombin concentrations. Once PAR1 is activated, its 
rapid signaling through G-proteins causes changes in 
platelet shape, synthesis and release of thromboxane A2, 
mobilization of P-selectin, rapid increase in intracellular 
calcium, and activation of the GPIIb-IIIa fibrinogen 
receptor, which culminates in platelet aggregation. PAR1 
and PAR4 do not signal simultaneously during platelet 
activation, instead they complement each other by evoking 
two distinct waves of intracellular calcium [169]. The 
signal of PAR1 is fast and quickly shut off. This is 
followed by a slow and prolonged signaling of PAR4. 
Unlike PAR1, PAR4 leads to irreversible platelet 
aggregation. Studies on human platelets have provided 
evidence that the high affinity PAR1 receptor forms stable 
complexes with PAR4, which enables thrombin to act as a 
bivalent functional agonist [126]. Platelet activation is 
important in haemostasis, but platelet activation and 
aggregation also play a critical role in thrombosis, which is 
responsible for the acute clinical manifestations of 
vascular atherothrombotic diseases, such as acute coronary 
syndromes (ACS), myocardial infarction (MI), ischemic 
stroke/transient ischemic attack, and symptomatic 
peripheral artery disease (PAD). Despite improvements in 
the management of ACS with established anti-platelet and 
anticoagulant therapies and revascularization techniques, 
many patients continue to suffer recurrent ischemic events, 
and bleeding rates are increased. However, inhibition of 
PAR1 is considered an attractive approach to antiplatelet 
therapy, because it may provide incremental ischemic 
protection without increasing bleeding. So, as below 
commented, several PAR1 antagonists have been 
developed and tested in clinical trials as antiplatelet drugs 
for cardiovascular diseases [170-173].  
Endothelial cells (ECs) express PAR1, PAR2, PAR3 
and PAR4, but, PAR1 is the major mediator of thrombin 
signaling in these cells [9, 11]. In normal pig and human 
coronary arteries, the activation of PAR1 induces 
endothelium-dependent vasodilation [174, 175]. However, 
in renal artery, thrombin elicits a biphasic response with 
initial endothelium-dependent relaxation, followed by 
endothelium-dependent contraction [176]. Therefore, 
PAR1 activation causes endothelium-dependent 
vasodilation and contraction depending on the vessel type. 
Vasorelaxation is due to PAR1-induced NO production by 
eNOS, while, contraction is mediated by thromboxane A2
(TXA2) and prostaglandin H2 (PGH2) [176]. Besides the 
effects on the modulation of the vessel tone, PAR1 
activation causes changes in vascular permeability in ECs 
[177-179], release of endothelium-derived coagulant and 
fibrinolytic factors, such as the endothelial tissue 
plasmiminogen activator [167], and mobilization of the 
von Willebrand factor (vWF) and P-selectin from Weibel-
Palade bodies [180, 181]. On the other hand, as 
commented in section 3, activation of PAR1 by APC 
induces anti-inflammatory, cytoprotective and barrier-
stabilizing effects in ECs [38]. Also in ECs, thrombin 
modulates, mainly via PAR1, the expression of genes 
related to haemostasis, cell growth and angiogenesis, 
cytokines, and cell adhesion [180, 182]. Under vascular 
pathologic conditions, thrombin upregulates these genes 
and their expression alterations may be linked to 
phenotypic conversion of endothelial cells into the pro-
inflammatory phenotype [182]. 
Under pathological conditions, such as tissue 
damage, thrombosis, hemorrhage and inflammation, 
proteases of the coagulation-fibrinolytic system and 
proteases-derived from immune and inflammatory cells are 
activated. This activation induces acute activation of 
PAR1, which, due to direct endothelial cell contraction, 
causes an increase in vascular permeability, resulting in 
plasma extravasation and edema [183]. Additionally, the 
endothelial activation of PAR1 accounts for the pro-
inflammatory responses to tissue injury, which include 
release of pro-inflammatory cytokines, increased surface 
expression of adhesion molecules, and platelet and 
leucocyte adhesion [184, 185]. Constitutive endothelial 
PAR1 activation seems to play a key role in 
vasculogenesis [186] and PAR1 signaling in ECs is 
necessary for proper vessel development [187, 188]. It has 
also been suggested that PAR1 activation may induce 
proliferation and migration of endothelial progenitor cells 
by an angiopoietin-dependent mechanism [189]. 
Furthermore, as below commented, thrombin is a potent 
angiogenic factor dependent on PAR1 activation and 
independent on fibribrin formation [190, 191]. These 
PAR1 effects on neovascularization and angiogenesis may 
contribute to the pathophysiology of vascular lesions. 
In contrast to ECs, the expression of PARs, 
particularly PAR1 and PAR2, is quite limited in normal 
vascular smooth muscle cells (VSMCs). However, both 
receptors are upregulated in VSMCs and macrophages of 
the vessel wall after vascular lesions [192, 193]. This 
higher expression suggests that PAR1 and PAR2 play an 
important role under vascular pathological conditions. In 
the presence of atherosclerotic lesions, the PAR1-induced 
endothelium-dependent relaxation is attenuated and, in 
advanced lesions associated with vessel wall thickening, 
the vasorelaxing response eventually disappears, becoming 
predominant the PAR1-induced and VSMC-mediated wall 
contraction response [194]. As a consequence, PAR1-
mediated effects on VSMC, such as contraction, 
proliferation, migration, hypertrophy, release of cytokines, 
and production of extracellular matrix are predominant in 
vascular lesions. In addition to atherosclerosis, angiotensin 
II-induced hypertension has been associated with 
upregulation of PAR1 in VSMCs [195]. A rapid and 
marked increase of PAR1 expression in VSMCs has also 
been associated with the proliferative and pro-
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inflammatory effects of thrombin in vascular remodeling 
and restenosis [196, 197]. 
In the heart, PAR1 is also expressed in ventricular 
myocytes [198] and cardiac fibroblasts [199]. Increased 
PAR1 expression has been found in the hearts of patients 
with ischemic and idiopathic dilated cardiomyopathy [200] 
and in the left ventricle of a mouse model of chronic heart 
failure [201]. In ventricular myocytes, PAR1 activation 
induces hypertrophy, with cytoskeletal reorganization, 
through activation of PKC- and RhoA/ROCK-dependent 
signaling pathways, presumably, via Gq and G12/13
proteins [84]. It has been suggested that this activation 
pathway is triggered by activation of MMP-9 [200]. 
Thrombin-mediated PAR1 activation induces atrial 
natriuretic factor expression [202] and activates the Na
+
/H
+
exchanger [203], increasing the persistent component of 
the Na
+
 current, which results in an uncontrollable sodium 
influx into cardiomyocytes [204] that may contribute to the 
cellular damage observed during cardiac ischemia.  
PAR1 is the most highly expressed GPCR in adult 
cardiac fibroblasts [199], where they promote the adverse 
left ventricular (LV) remodeling that underlines the 
development of ischemic cardiomyopathy. It has been 
shown that the PAR1 antagonist SCH79797 inhibits 
thrombin–mediated ERK1/2 phosphorylation, TGF-β and 
type I procollagen production, MMP-2 and -9 activation, 
and myofibroblast transformation in vitro. Furthermore, 
this PAR1 antagonist attenuated LV dilation and improved 
systolic function of the reperfused myocardium after 
myocardial ischemia [205]. 
6.2. Inflammation and immune system
As aforementioned, thrombin, through activation of 
PAR1, triggers many responses associated with 
inflammation, including endothelial cell activation, mast 
cell degranulation, increased adhesion of neutrophils to the 
endothelium, platelet aggregation and chemotaxis of 
neutrophils, and induction of cytokine release from 
epithelial cells, VSMCs, and ECs [19]. These effects may 
be responsible for the hallmarks of inflammation, such as 
increased blood flow and temperature, pain, edema, and 
loss of function. Immune cells are highly involved in the 
inflammatory responses to PARs activation, although the 
mechanisms by which these receptors exert their effects on 
these cells related to inflammation are still poorly 
understood [7, 19, 206]. Most of the studies related to the 
actions of PARs in inflammation and the immune system 
have been carried out in vitro or in animal models from 
different species. Taking into account the species and 
cellular specific expression of these receptors, the 
comparison of results is difficult. 
PAR1 signaling in inflammation is complex since, 
depending on the type and stage of the inflammatory 
disease [207, 208], the activating protease can be different 
and the response to activation may be either inflammatory 
or anti-inflammatory [14, 19, 206]. In general, thrombin 
triggers inflammatory responses, while APC triggers the 
anti-inflammatory ones. 
PAR1 plays a pivotal role in sepsis, an exaggerated 
and acute inflammatory response that can have several 
etiologies, also known as systemic inflammatory response 
syndrome (SIRS), with high incidence and mortality in 
ICU patients and, currently, with  few and low response 
treatments [209, 210]. This syndrome develops when an 
initial appropriate innate immune response, usually to a 
microbial infection, becomes amplified and then 
dysregulated. Under these conditions, high levels of 
pathogen-associated molecular mediators, such as 
endotoxin, lipopolysaccharide (LPS) or other microbial 
components, can initiate a massive release of host-derived 
mediators, including cytokines, chemokines and products 
of the complement system that activate ECs. As a 
consequence, the endothelial barrier is disrupted causing 
fluid leakage from the intravascular space. This contributes 
to hypovolemia and hypotension and to the septic shock. 
Coagulation is activated by the induction of TF on 
monocytes and ECs, where PAR1 plays important roles in 
the crosstalk between coagulation and inflammation, and 
may further contribute to organ failure and death. In this 
regard, based on its PAR1-mediated protective anti-
inflammatory and endothelial barrier-stabilizing 
properties, APC is the only approved agent for the 
treatment of severe sepsis, although it has shown only 
modest mortality rate reduction [211]. On the other hand, 
in a recent study in human sepsis patients, a highly 
significant correlation has been found between elevated 
plasma levels of MMP-1 and deaths at 7 and 28 days after 
diagnosis [212]. Moreover, in septic mice, blockage of 
MMP-1 activity suppressed endothelial barrier disruption, 
disseminated intravascular coagulation, lung vascular 
permeability, as well as the cytokine storm, and improved 
survival. These effects were lost in PAR1 deficient mice. 
Studies in animal models have shown contradictory 
results on the role of PAR1 in the gut, that is, both pro-
inflammatory and anti-inflammatory [14, 213]. The results 
depended on the cell, animal species and time frame of the 
assays. Further studies are needed to clarify the potential 
roles of PAR1 in gut diseases. PAR1 are highly expressed 
in the gastrointestinal (GI) tract, where it has been detected 
in ECs of the lamina propria, epithelial cells, SMCs, 
enteric neurons, fibroblasts and some immune cells 
(neutrophils, mast cells, lymphocytes, monocytes, and 
macrophages) [213]. Activation of this receptor has been 
involved in several aspects related to the gut physiology, 
such as: ion transport, inflammation, permeability, 
motility, sensory functions, and proliferation. Activation of 
PAR1 in neurons of mouse colon inhibits chloride 
secretion, suggesting that PAR1 activation on enteric 
nerves might modulate ion transport across the epithelium 
[214]. PAR1 increases intestinal permeability by direct 
activation on epithelial cells [215] and it is involved in the 
modulation of GI motility [216]. Thus, PAR1 activation 
induces contraction in mouse and rat gastric smooth 
muscle in a prostaglandin dependent manner [217], while 
in longitudinal and circular muscles of the colon inhibits 
contractile effects [218, 219]. Concerning inflammation, 
PAR1 appears to play both pro-inflammatory and anti-
inflammatory roles in different models of inflammatory 
bowel diseases (IBD). In mouse models of colitis, PAR1 
activation enhanced and prolonged inflammation, whereas 
PAR1 antagonists decreased mortality and severity of 
colitis [207]. PAR1 induced colitis was partly due to an 
increase in intestinal barrier permeability, but also to direct 
activation of B and T lymphocytes.  
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Table 2. Summary of cell PAR1 expression and main physiological functions and dysfunction pathologies 
Cell expression Physiological function Dysfunction pathologies 
Cardiovascular 
system
Platelets Secretion and aggregation in hemostasis Thrombosis, ACS, MI, PAD
ECs
Coronary artery vasodilatation
APC-mediated anti-inflammation, 
cytoprotection and barrier stabilization
Increased vascular permeability, edema, 
inflammation, neovascularization and angiogenesis 
VSMCs Low expression
Increased expression in vascular lesions, wall 
contraction, cell proliferation, migration and 
hypertrophy
Ventricular 
myocytes
Low expression
Increased expression in ischemic and idiopathic 
cardiomyopaties, hypertrophy, cellular damage
Cardiac 
fibroblasts
Low expression Increased expression in  ischemic cardiomyopaties
Inflammation and 
immune system
ECs Cell activation, cytokine release
Sepsis (Inflammation, endothelial barrier 
disruption, hypovolemia, hypotension, coagulation)
In the gut: alteration of ion transport, inflammation, 
permeability, motility, and proliferation. Involved 
in IBD, colitis, and IBS
Bladder inflammation
In the respiratory system: pulmonary diseases 
coupled to inflammation and coagulation (ALI, 
pulmonary fibrosis, asthma, and bronchitis) 
Involved in allergy processes and delayed immune 
responses
Mast cells Degranulation
Platelet Aggregation
VSMCs Cytokine release
SMCs
Cytokine release, contraction of bronchial 
rings
Enteric neurons Activation of chloride secretion
Lung fibroblasts
Synthesis and release of extracellular matrix 
proteins, growth factors, and 
proinflammatory agents
Neutrophils
Increased adhesion to endothelium, 
chemotaxis
Eosinophils Eosinophil chemotaxis
Monocytes
Increase of [Ca2+] level, modulation of 
cytokine release, enhancement of kill 
bacteria ability
Macrophages
Increase of [Ca2+] level, modulation of 
cytokine release
hMCs Enhancement of chemokine secretion 
Nervous system
Neurons
Induction of cell morphological changes
Neuronal development and plasticity, 
learning and memory
Thrombin concentration dependent cell 
protection/damage
APC-mediated stabilization of BBB and 
neuroprotection
Epileptic seizure onset
Neuroinflammation and neurodegeneration (stroke, 
Alzheimer´s and Parkinson´s diseases, HIV-
associated dementia and MS)
Astrocytes
Induction of cell morphological changes, 
cell proliferation, glutamate release, 
activation of NMDA receptors in neurons
Microglia
Modulation of inducible iNOS expression 
and proinflammatory cytokines, activation 
of NADPH
Cancer and 
angiogenesis
Platelets Secretion and aggregation in hemostasis Hipercoagulation-cancer association
Cancer cells Activation of PAR1 signaling cascade
Overexpression in melanoma, breast, prostate, 
pancreas, ovarian, colon, head and neck, and lung 
cancers, endometrial carcinoma, and aggressive 
leukemias
Secretion of cell growth and angiogenesis factors
Activation of cell growth, invasion , and metastasis
Activation of oncogenes
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PAR1 expression was upregulated in biopsies from 
Crohn´s disease or ulcerative colitis patients. On the other 
hand, a protective role has been ascribed to PAR1 during 
the course of the Helicobacter pylori infection in the gut, 
where PAR1 activation suppressed the production of pro-
inflammatory cytokines and lowered the host 
inflammatory response [220]. A potential role of PAR1 
activation has been suggested in the initial inflammatory 
events for the development of irritable bowel syndrome 
(IBS) [213], often associated with a previous history of 
infectious colitis. As already commented, PAR1 has been 
associated with many of the pathogenic symptoms of IBS, 
such as inflammation, altered GI motility, and increased 
permeability. Interestingly, since functional PAR1 is 
expressed on afferent sensory fibers in the gut, a role for 
this receptor in nociception, activating opioid pathways, 
has been suggested [221, 222], which could contribute to 
inhibit pain symptoms associated with IBS. 
PAR1 is expressed in kidney eurothelial cells, where 
its activation, by locally generated thrombin or other 
proteases present in the urine, may mediate bladder 
inflammation by inducing the release and expression of the 
macrophage migration inhibitory factor (MIF), a pivotal 
mediator of acute and chronic inflammation [223]. On the 
other hand, based on the fact that PAR1 is upregulated in 
glomeruli from diabetic mice, it has been suggested that 
PAR1 upregulation may play a role in the progression of 
glomerulosclerosis and abnormal urinary excretion of 
urinary albumin in diabetic nephropathy [224].   
In the respiratory system, PAR1 is abundantly 
expressed in various cell types in the airways, such as 
epithelial cells, SMCs, fibroblasts and immune cells and its 
expression is up-regulated during development of 
pulmonary diseases, which are coupled to inflammation 
and procoagulant activity, such as pulmonary fibrosis, 
asthma, and bronchitis [7, 163, 164]. In the normal 
uninjured lung, the alveolar haemostatic balance is 
generally antithrombotic and pro-fibrinolytic. However, in 
both acute lung injury (ALI) and chronic lung diseases, 
such as pulmonary fibrosis, the balance seems to be shifted 
in favor of pro-coagulant and anti-fibrinolytic activity 
[164]. These pathologies are characterized by diffuse 
alveolar damage, disruption of the alveolar capillary 
barrier, pulmonary edema, neutrophilic inflammation, and 
extravascular intra-alveolar accumulation of fibrin in 
pulmonary fibrosis [225]. PAR1 is the main protease 
receptor in lung fibroblasts, where it induces synthesis and 
release of extracellular matrix proteins (collagen, tenascin) 
[163, 226], growth factors (CTGF, PDGF) [227, 228], and 
the proinflammatory agents IL-6 and IL-8 [163]. PAR1 
activation also induces cell proliferation [229] and 
differentiation of fibroblasts to myofibroblasts [230], 
which are the key effector cells in pulmonary fibrosis.  
Furthermore, PAR1 exerts a contraction effect on human 
bronchial rings [231], while, in mouse tracheal SMCs it 
exerts a dual role of constriction and relaxation [232, 233]. 
It seems that this last effect is mediated by the release of 
the anti-inflammatory and relaxant prostaglandin E2
(PGE2) after PAR1 activation.  
Many of the commented inflammatory responses to 
PAR1 activation are mediated by immune cells. This 
receptor is expressed in neutrophils, eosinophils, 
monocytes, macrophages, lymphocytes, dendritic cells, 
and mast cells, although its functionality in some of these 
cells remains to be verified [159, 206]. Thus human 
neutrophils isolated from male or nonpregnant female 
healthy volunteers do not express PAR1, but it is 
expressed in neutrophils from normal or preclamptic 
pregnant female donors [234]. Human eosinophils express 
PAR1 and its activation by thrombin stimulates eosinophil 
chemotaxis [235, 236]. Thrombin and PAR1-APs 
stimulate and increase the levels of [Ca
2+
] in human 
monocytes [237]. The activation of the receptor in these 
cells upregulates the expression and release of monocyte 
chemoattractant protein-1 (MCP-1) [237], and the 
plasmin-mediated activation induces the anti-apoptotic 
effect of plasminogen observed in these cells [238]. Also 
in monocytes, thrombin and PAR1-APs modulate the 
production and release of cytokines, including IL-6, IL-8, 
platelet factor-4, platelet basic protein, and RANTES 
[206]. Additionally, treatment of human monocytes with 
thrombin or PAR1-APs enhances the ability of these cells 
to kill bacteria [239]. 
Human macrophages express a similar PAR1 pattern 
to that of their monocyte precursors. A higher expression 
of PAR1 has been shown in alveolar macrophages of 
smokers than nonsmokers [240]. Activation with PAR1-
APs increases intracellular [Ca
2+
], upregulates the 
expression and release of MCP-1 [206], and stimulates 
elastase secretion from macrophages [241]. In fibrotic liver 
diseases PAR1 is upregulated and a recent report has 
associated the effect of PAR1 signaling on the induction of 
chemotaxis on bone marrow derived macrophages with a 
fibrotic response of the liver to a recurrent injury [242].  
T lymphocytes expresses PAR1 [243] and its 
thrombin-mediated activation increases intracellular 
[Ca
2+
], activates PKC [244, 245] and increases IL-6 
secretion [246], whereas PAR1 is absent in B 
lymphocytes. However, there is lack of information 
concerning the involvement of PAR1 signaling in the 
regulation of T cell functions and T cell-mediated diseases, 
as well as, in those of dendritic and mast cell functions. 
Although human dendritic cells express PAR1, little is 
known on its physiological and pathophysiological 
significance [206, 247]. It seems that the PAR1-S1PR3
signaling in dendritic cells plays a critical role in 
regulating the amplification of inflammation in the sepsis 
syndrome [130]. Human mast cells (hMCs) are recognized 
as key players in the initiation of allergic diseases and also 
as participants in the host response to certain parasitic 
infections [206]. Skin hMCs expresses PAR1 [248] and 
PAR1 activation in mouse MCs enhances IL-6 secretion 
[249] and induces the adhesion of bone marrow-derived 
MCs to fibronectin and laminin [250]. The potent 
chomoattractant RANTES, crucial player in the 
pathogenesis of allergy, upregulates the expression of 
PAR1 in mouse MCs and induces the production of IL-13 
[251]. In human oral keratinocytes PAR1, along with 
PAR2, triggers innate immune responses signaling via p38 
and ERK1/2 MAP kinases. PI3K exerts a negative 
regulatory role in this signaling through the inhibition of 
p38 signaling. In this way, both PAR1 and PAR2 keep the 
innate immune responses of human oral keratinocytes in 
balance [252]. 
Although most pathogens trigger a delayed immune 
response, in some situations, pathogen-derived proteases 
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can trigger an immediate innate immune response, in part 
by regulating the activity of PAR1. This regulation can be 
mediated through both receptor activation or disarm. This 
is the case, already commented in section 3, of the 
gingipains, implicated in human periodontitis produced by 
Porphyromonas gingivallis, which activate both PAR1 and 
PAR2 [63-67]. In Leishmania infection, Leishmania
promastigotes, through their surface protease, 
leishmanolysin or gp63, activates PAR1 in the host 
macrophages. This activation raises the cytosolic [Ca
2+
], 
activating the Ca
2+–dependent protease -calpain. The 
virulence of Leishmania has been related to the expression 
of surface gp63 [253]. PAR1 has also been related with the 
pathogenicity of influenza A virus in mice. PAR1 
expression is increased in infected mice [254], and it 
seems that PAR1 activation decreased survival and 
increased lung inflammation after influenza infection in a 
plasminogen-dependent manner, while both PAR1 
antagonist administration or PAR1 deficiency protected 
mice from infection [255]. However, the signaling 
mechanism of this PAR1 pathogenic role in virus infection 
is unknown. 
6.3. Nervous system
PAR1 expression is widespread, but with low 
intensity, in the late embryonic and early postnatal nervous 
system, becoming more pronounced and confined to 
particular neuronal cells in adult animals [256]. This 
receptor is abundant in the hippocampus, particularly in 
the pyramidal layers of the CA2 and CA3 regions, and low 
level of expression has been observed in the cortex, 
thalamus, hypothalamus, striatum, and amygdala [25]. 
PAR1 is expressed in neurons, astrocytes, microglia, and 
oligodendrocytes [257-262]. These cells also express 
PAR1-activating serine proteases [8, 24, 160]. The local 
expression of these proteases and PAR1 indicates that this 
receptor plays an important role in physiological functions 
in the brain related to neuronal development and plasticity. 
On the other hand, the expression of both PAR1 and its 
activating proteases is increased in the brain of patients 
with neurodegenerative diseases, such as stroke, 
Alzheimer’s disease, Parkinson’s disease, and HIV-
associated dementia [25]. The level of signaling of PAR1 
is also altered during disease due to the extravasation of 
plasma proteases through a perturbed blood-brain barrier 
(BBB), such as in acute injuries (for example, in trauma or 
stroke). In injured brains, thrombin mediates, via PAR1, 
dual opposite effects. Low concentrations of thrombin 
rescue neuronal cells from death after brain insults, while, 
high concentrations of this protease exacerbate brain 
damage [25]. Oh the other hand, APC signaling through 
PAR1 can favorably regulate diverse pathways in the 
neurovascular unity in non-neuronal cells and neurons 
during acute or chronic CNS insults, leading to 
stabilization of BBB, neuroprotection and control of 
neuroinflammation [160]. 
During neuronal development, thrombin signaling 
through PAR1 has a direct effect on cell morphology of 
astrocytes, fetal neurons, and neuroblastoma cells. Low 
concentrations of thrombin induce neurite retraction in 
neurons and reverse the stellation in astrocytes [25]. The 
protein RhoA, via PAR1 signaling through Gα12/13, has 
been implicated in the thrombin-induced morphological 
changes in neurons and astrocytes. This signaling requires 
the interaction of PAR1 with creatinine kinase and heat 
shock protein 90 (Hsp90) [263-265]. Thrombin, also via 
PAR1, induces cell proliferation in astrocytes, signaling 
through Gαi/o [25], and regulates synaptogenesis in the 
peripheral nervous system [266, 267]. PAR1 has also been 
implicated in synaptic plasticity and learning and memory 
in the brain [25, 268]. PAR1 activation induces glutamate 
release from astrocytes, which activates NMDA receptors 
on adjacent neurons of the hippocampus [135, 269]. PAR1 
deficiency in mice impairs learning, passive avoidance 
behavior, and fear-conditioning freezing [270]. Both 
thrombin and APC, via PAR1, participates in the NMDA-
mediated regulation of long term potentiation (LTP) of 
synaptic transmission. Thrombin induces a slow onset 
LTP, while APC shifts the threshold of LTP towards 
further potentiation and, besides PAR1, requires activation 
of S1PR1 and intracellular Ca
2+
 stores [271]. Plasmin may 
also participate in the potentiation of NMDA synaptic 
currents in CA1 pyramidal neurons through PAR1 
activation in astrocytes [43]. It has been suggested that the 
potentiation of NMDA receptor function by PAR1 
activation may also increase the excitability of dentate 
granule neurons of hippocampus [272] and underlie the 
PAR1-dependent neuronal damage after brain injury [133]. 
On the other hand, thrombin and PAR1 have been 
implicated in the onset of seizures. Thrombin causes an 
increase in spontaneous action potential discharges of C3 
and C1 pyramidal neurons that is blocked by selective 
PAR1 antagonists. These results, along with the higher 
expression of PAR1 in striatum lucidum of C3, suggest 
that thrombin, via PAR1, is implicated in epileptic seizure 
onset [161]. 
Microglia cells are the major immune effectors in the 
brain, and activated microglia participates in 
neuroinflammation around injured areas in the brain. In 
microglia, thrombin mediates the expression of inducible 
iNOS and several proinflammatory cytokines [25]. 
Thrombin also activates, via PAR1, NADPH oxidase, an 
important source of reactive oxygen species (ROS) during 
inflammation in microglia in the hippocampus. So, several 
neurodegenerative disorders have been associated with 
thrombin-induced neuroinflammation in microglia, such as 
stroke, Alzheimer’s disease, Parkinson’s disease, and HIV-
associated dementia. PAR1-mediated activation of 
astrocytes also contributes to neuroinflammation in the 
brain [25]. On the other hand, several studies in astrocytes 
have indicated that thrombin, in a concentration dependent 
manner, induces, via PAR1 activation, the release of 
cytokine-induced neutrophil chemoattractants (CINCs) 
that enhance cell survival in astrocytes [273, 274]. These 
chemokines, released from astrocytes upon thrombin 
stimulation, protect cortical neurons from apoptosis and 
might be responsible, in part, of the protective actions of 
low concentrations of thrombin after brain injury [275].  
Thrombin is responsible for brain edema formation 
after intracerebral hemorrhage or after focal cerebral 
ischemia. Under these conditions, a variety of 
proimflammatory mediators are generated in the brain and 
thrombin-induced neuroinflammation seems to be 
involved into neurodegeneration in stroke [25]. In vivo
studies have demonstrated that PAR1 activation 
PAR1 Receptor/Protein Interactions 
14 
significantly increases infarct volume in the brain after 
transient focal cerebral ischemia [276]. PAR1 activation 
by thrombin induces apoptosis in hippocampal neurons 
through activation of RhoA and the MAPKs cascade [97, 
277]. Both signaling molecules are involved in 
neurodegeneration and neuroprotection in stroke. Thus, 
cell death and cell survival may share initial signaling 
proteins, but differences in amplitude, as well as in 
duration of signal may result in opposite final 
consequences [278]. On the other hand, MMP-9 is 
increased in brain after intracerebral hemorrhage and 
contributes to the thrombin-mediated PAR1 neurotoxicity 
[279, 280], as this metalloprotease can degrade 
extracellular matrix and cause BBB disruption. 
In Alzheimer’s disease, thrombin plays an important 
role in its pathogenesis. Thus, oxidative stress and 
neuroinflammation is present in this disease [281]. On the 
other hand, as already commented, thrombin and PAR1 are 
upregulated in the brains of patients suffering this disease. 
Both proteins are accumulated in extracellular and 
intracellular neurofibrillary tangles, senile plaques, and 
reactive microglia cells [282, 283]. There is evidence that 
thrombin, through activation of PAR1 and PAR4 induces 
hyperphosphorylation and aggregation of tau protein in 
hippocampal neurons. This effect seems to be mediated by 
activation of ERK1/2 [284]. Conversely, thrombin 
attenuates Aβ toxicity via PAR1, but this effect is not clear 
and needs further investigations [285]. High levels of 
expression of the transcription factor HIF-1, which 
regulates proinflammatory gene expression, and of MMP-
1 have been detected in Alzheimer’s disease brains. 
Besides, thrombin induces upregulation of HIF-1 and 
MMP-1 in brain endothelial cells [283, 286]. Taking into 
account these results, it has been suggested that thrombin-
induced alterations in brain microcirculation might also 
contribute to the pathological processes of Alzheimer’s 
disease [25]. 
Oxidative stress and neuroinflammation are the most 
significant features of Parkinson’s disease. Both thrombin 
and PAR1 are upregulated in the vessel wall in the 
substantia nigra pars compacta of Parkinson’s disease 
patients [287]. However the role of PAR1 in Parkinson’s 
disease is not clear, as both neurodegenerative and 
neuroprotective effects of the thrombin-mediated PAR1 
activation on Parkinson’s disease models have been 
reported. Thus, PAR1 deficiency, as well as administration 
of PAR1 antagonists, reduced dopaminergic neuron 
damage and microgliosis in a model of induced 
Parkinson’s disease [288]. In another model, PAR1-
specific antagonists diminished the expression of 
microgliar inflammatory cytokines induced by -
synuclein, a protein with a key role in the pathogenesis of 
Parkinson’s disease [289]. In contrast, it has been found 
that PAR1, activated by thrombin, mediates 
neuroprotection in the rat 6-hydroxydopamine model of 
Parkinson’s disease and reduces dopaminergic terminal 
cell loss [290]. 
Activation of the coagulation cascade has been 
associated with inflammation in the experimental 
autoimmune encephalomyelitis model of multiple sclerosis 
(MS) [291]. Considering the key role of thrombin in 
coagulation, it has been suggested that this protease may 
play an important role in MS [25]. Besides, the 
predominant expression of PAR1 in oligodendrocytes also 
indicated an important role of this receptor in MS [261]. 
On the other hand, it has also been reported that APC-
mediated activation of PAR1 results in neuroprotection in 
animal models of MS and amyotrophic lateral sclerosis 
(ALS) [160].  
6.4. Cancer and angiogenesis
Over the last years, abundant evidences have 
contributed to associate dysregulation of PAR1 activity 
with cancer, including: i) high correlation between 
hypercoagulation disorders and cancer, ii) overexpression 
of PAR1 in cancer patients, iii) relationship between 
dysregulation in the PAR1 signaling cascade with cancer 
development pathways, and iv) strong involvement of 
PAR1 in angiogenesis processes.  
6.4.1.Hypercoagulation-cancer association 
The relationship between thrombosis and cancer 
[292], which was first described by Armand Trousseau in 
1865 [293], Venous thromboembolism (VTE) is frequenly 
observed in cancer patients and its incidence depends on 
the cancer type. Clinical symptoms of VTE vary from 
asymptomatic deep vein thrombosis (DVT) to fatal 
pulmonary embolism (PE). It is considered that 10-20% of 
cancer deaths could be due to PE, rather than to the cancer 
itself [294], and it seems that tumor histology is related to 
the risk of developing PE. In necropsy studies, ovarian 
cancers had the highest percentage (34.6%), whereas 
cancers of the oesophagus and larynx, and lymphomas had 
the lowest rates (0.5-6%) [295]. VTE is the second most 
common cause of death in cancer patients [296]. On the 
other hand, cancer is a well-known predictor for VTE and 
patients with cancer undergoing surgery have increased 
risk of developing post-operative DVT [297].Often, 
thrombosis is the first clinical manifestation of cancer. It 
has been reported that approximately 10% of patients who 
developed spontaneous thrombosis develop cancer several 
years later [298]. In addition, cancer patients who develop 
thrombosis have worse prognosis [299, 300]. A recent 
report shows that patients with digestive tract cancers tend 
to form less permeable, and more resistant to lysis, fibrin 
clots than controls [301].  
Increasing data from prospective randomized clinical 
trials indicate important benefits of anticoagulants on 
cancer patient survival [292, 297, 302, 303]. This 
suggestion is supported by diverse results, which includes 
the use of heparin or low-molecular weight heparin 
(LMWH) instead of warfarin, [304-307]. Comparative 
clinical trials of LMWH versus warfarin and heparin point 
out increases in survival indices of the patients treated with 
LMWH [308, 309]. Additionally, it has been described 
that anticoagulants are able to raise the functional activity 
of natural killer cells in cancer patients, and in an animal 
model of lung cancer [310]. Furthermore, it has been 
reported that platelets from anticoagulated patients have 
decreased VEGF release and angiogenic potential [311]. 
These data have been considered to suggest that 
antithrombotic agents can increase survival and decrease 
metastasis in cancer patients through attenuation of platelet 
angiogenic potential.  
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Recent studies show that diverse oncogenic events 
link haemostasis and cancer, mainly through the 
crossroads between TF and PAR1 [312]. It seems that TF 
may act as molecular switch that controls the transition 
between dormant, latent, and progressive/metastatic 
disease [312-314]. TF initiates the coagulation cascade, 
which, through thrombin and PAR1, activates platelets. 
Thrombin/PAR1 signaling has been associated with the 
upregulation of TF in diverse cancer cell lines [297], 
increase in tumor production of VEGF and decrease in the 
antiangiogenic regulatory protein thrombospodin [314]. 
6.4.2.Overexpression of PAR1 in cancer 
The association of PAR1 expression with cancer has 
been recognized for an numerous group of tumors [166, 
315]. Thus, overexpression of PAR1 has been observed in 
biopsy samples from patients with melanoma [316], 
endometrial carcinoma [317], cancers from breast [318, 
319], prostate [320-322], pancreas [323], ovarian [324], 
and colon [325], squamous cell carcinoma of the head and 
neck [326], and in lymphocytes and granulocytes from 
aggressive human leukemias [327]. A analysis of a group 
of mammary carcinoma cell lines showed high levels of 
expression of the gene hPar1 in aggressive metastatic cells 
(MDA-435 or MCF10AT3B), lower levels in moderately 
metastatic cells (MDA-231 or MCF10T), and very low 
levels to none in non-metastatic breast cancer cells (MCF-
7, ZR-75, or MCF10A) [318]. Recent studies indicate that 
in breast cancer cells the expression of the hPar1 gene is 
controlled by estrogen [319] and progesterone [328], and 
overall survival is shorter in breast cancer patients that are 
positive for the estrogen receptor (ER) and PAR1[319] 
[329]. PAR1 expression is also increased in patients with 
non-small-cell lung cancer, mainly in patients with 
adenocarcinomas [330, 331], and in stromal fibroblasts of 
malignant tissues in comparison to fibroblasts from normal 
or benign breast tissue samples [332]. In these patients, 
PAR1 was an independent prognostic factor for reduced 
survival, and it has been shown that it is a potential risk 
factor for recurrence in prostate cancer [266]. Recent 
studies have demonstrated that the PAR1-506 I/D 
polymorphism might be an important prognostic factor for 
breast cancer, esophagus adenocarcinoma, and gastric 
cancer patients [333-335]. Experimental studies on animal 
models and cancer cell lines also support the relationship 
between PAR1expression and tumor growth and 
metastasis. Thus, PAR1 induces oncogenic transformation 
of NIH 3T3 fibroblasts [336]. Knocking down PAR1 
expression in metastatic MDA-MB-231 breast cancer cells 
reduces significantly their metastatic potential, whereas 
PAR1 overexpression in low metastatic MCF-7 breast 
cancer cells activates growth and invasion in a mouse 
model [50]. Similarly, knocking down the PAR1 
expression in lung adenocarcinoma cells inhibited cell 
progression [337]. Stable PAR1 antisense melanoma cells 
showed reduced cell proliferation and invasion in vitro
[338]. Injection of these cells into nude mice afforded very 
few and occasional small tumors, while advanced and 
vascularized tumors were detected with injection of the 
highly metastatic human melanoma cells A375-
SM.Likewise, systemic administration of PAR1 small 
interfering RNA (siRNA), enclosed in neutral liposomes, 
significantly reduced tumor growth, weight, and metastatic 
lung colonies in nude mice with subcutaneous implants of 
melanoma cells A375-SM [339]. The 
immunohistochemistry study of the tumor samples 
indicated a parallel reduction in VEGF, interleukin-8, and 
matrix metalloprotease-2 (MMP-2) expression levels, as 
well as in blood vessel density. These results suggest that 
PAR1 regulates tumor cell growth and metastasis by its 
action upon angiogenic and invasive factors. Most human 
cancers derive from epithelial cells, and it has been 
observed that although hPar1 is overexpressed in many 
malignant tumors, the levels of this gene in physiological 
invasion processes are high only in the placenta during the 
first trimester of pregnancy [166]. 
6.4.3. PAR1 Activation and signaling related to cancer  
PAR1 is responsible for the direct downstream 
mitogenic effects of thrombin on tumor cells and for its 
indirect effects through platelet-tumor interactions. Among 
these later activities, it has been proposed that thrombin 
can increase tumor growth indirectly by activating 
platelets and activating platelet-tumor cell interaction 
[165]. Platelet activation induces the release of tumor cell 
growth and angiogenesis factors, such as platelet-derived 
growth factor (PDGF) [340], VEGF [341], and 
angiopoietin-1 [342]. It has also been described that 
platelets produce lysophosphatidic acid (LPA), which 
stimulates tumor cell growth, by binding to its LPA1 
receptor in breast (MDA-BO2) and ovarian (CHO) cancer 
cells [343]. Besides to its contribution to the adhesion of 
endothelial cells and the development of collateral vessels, 
platelet-tumor aggregates protect tumor cells from natural 
killer cells [344]. These aggregates embolize, leading to 
ischemia and endothelial cell damage   [302]. As a result, 
tumor cells and platelets bind more strongly to the 
subendothelial basement membrane and matrix [345]. 
Finally, tumor cells are released into the parenchyma 
leading to neoangiogenesis [302]. 
Besides thrombin, other PAR1 activating proteases 
are involved in tumor cell survival, motility, migration and 
invasion, at least in experimental in vitro studies. Thus, it 
has been reported that APC increases invasion and 
chemotaxis of breast cancer cells by activating specific 
signaling pathways through activation of PAR1 and EPCR 
[346-348]. As indicated in section 3, the activation of 
PAR1 by either KLKs [19, 48] or MMPs [54, 349] has 
also been related to cancer. 
With respect to MMPs, it is well-known that these 
metalloproteases are important in growth, invasion, and 
metastasis of malignant tumors [350]. In particular, tumor 
expression of MMP-1 is associated with bad prognosis in 
melanoma, breast, ovarian, colorectal, pancreatic and 
gastric cancers [351]. Expression of MMP-1 is also related 
to increased angiogenesis in xenograft models of 
melanoma, breast, and prostate tumors [53]. Although the 
collagenolitic activity of MMP-1 may help angiogenesis 
by clarifying extracellular space to enable vessel branching 
[352], recent works have suggested that the angiogenic 
activity of tumor produced MMP-1 could also be due to 
the activation of PAR1 expressed in endothelial cells [50, 
53, 353, 354]. On the other hand, although MMP-9, an 
inductor of tumor cell invasion, does not activate PAR1, 
this protease is induced by the activation of this receptor 
by thrombin [355]. PAR1 and MMP-9 are coexpressed in 
PAR1 Receptor/Protein Interactions 
16 
osteosarcomas and it has been shown that activation of 
U2-OS osteosarcoma cells with thrombin or a PAR1-AP 
induces pro-MMP-9 release, as well as its surface-
associated expression and proteolytic activity. The 
stimulation of MMP-9 by thrombin also produces a PI3K-
mediated increase in β1-integrin expression on the cell 
surface, which is required for invasion [355].
Several PAR1 signaling pathways also have a clear 
implication in cancer and angiogenesis, such as 
transactivation of EGFR. A study on the PAR1 
transactivation cascade of EGFR in HT-29 colon cancer 
cells [356] revealed the following activation sequence: (a) 
a MMP-dependent release of the transforming growth 
factor-α (TGF-α); (b) TGF-α-mediated activation of EGFR 
and EGFR phosphorylation; (c) activation of ERK1/2 and 
cell proliferation. The association between these actions 
was proved by the fact that stimulation of cell proliferation 
and ERK1/2 by activation of PAR1 was reversed by the 
MMP inhibitor batimastat, TGF-α neutralizing antibodies, 
EGFR binding domain blocking antibodies, and EGFR 
tyrosine kinase inhibitors. It has been also proved that 
activation of PAR1 by thrombin induces persistent 
transactivation of EGFR and ErbB2/HER2, via prolonged 
ERK1/2 signaling, in invasive breast carcinoma, but not in 
normal mammary epithelial cells [93]. Transactivation of 
EGFR by thrombin-mediated activation of PAR1 has also 
been associated with the aggressiveness of inflammatory 
breast cancer, a very aggressive form of epithelial breast 
cancer [357].  
Aberrant PAR1 trafficking, resulting in receptor-
populated cell surfaces and prolonged and persistent 
signaling has also been shown in breast cancer. The PAR1 
C-tail is responsible for this persistent signaling. It has 
been demonstrated that, in breast cancer cells, there is an 
association of the proteins Etk/Bmx and Shc to form a 
physical complex with the PAR1 C-tail via its PH domain 
[358].  
It has been reported that thrombin stimulates the 
expression and secretion of VEGF and interleukin-8, via 
activation of PAR1, in melanoma [339] and prostate 
cancer cells [359]. This upregulation was reversed by 
inhibitors of ERK or PI3K kinase pathways, and 
completely deactivated by PAR1 specific siRNA. In 
human endometrial stromal cells, the activation of PAR1 
by thrombin or PAR1-APs also promoted the production 
of VEGF, MMP-1 and active MMP-2 [360]. On the other 
hand, PAR1 can stimulate cell migration, via Rac and 
focal adhesion kinase (FAK), by activation of the tumor 
progression locus 2, tumor necrosis factor α and CD40 
signals [86]. 
Different groups have reported that overexpression of 
the gene hPar1 in mice mammary glands rises the 
expression levels of Wnt-4 and Wnt-7b, both linked to a β-
catenin nuclear stabilization [166, 361, 362]. This 
enhancement of β–catenin stabilization has been noted 
only throughout pregnancy and in stabilized epithelial 
tumor cell lines. 
PAR1 expression has also been related to some 
transcriptional factors associated with cancer [166]. For 
instance, analysis of the hPar1promoter showed the 
presence of androgen response elements (ARE), and 
androgens regulate hPar1 expression in prostate cancer 
biopsy specimens . After hormone ablation treatment, 
tumor tissues from the same individuals presented very 
little to none hPar1 expression and significantly reduced 
tumor size [363]. Also in prostate cancers, the early 
growth response-1 (Egr-1) gene induces overexpression of 
hPar1, and a direct correlation between the degree of 
cancer malignancy, PAR1 expression, and EGR-1 
expression has been observed in prostate biopsy samples. 
Expression of PAR1 and EGR-1 was not observed in non-
cancerous cells. However, a high distribution and 
colocalization of both receptors were detected in 
neoplastic tissues [364]. Finally, the tumor suppressor p53 
also acts on hPar1 as one of its targets genes, regulating its 
expression [166]. It has been observed that hPar1
expression is low in cancer cell lines expressing wild-type 
p53, whereas it is overexpressed in cell lines lacking p53 
expression or expressing mutant forms [365]. 
6.4.4. PAR1 and angiogenesis  
Angiogenesis is an essential process in tumor growth 
[165, 191], which is affected by potent angiogenic factor 
thrombin, whose effect is dependent on PAR1 activation 
and independent of fibrin formation [190]. Thrombin and 
the PAR1-AP SFLLRNPNDKYEPF enhance 
neoangiogenesis 2-3-fold in the chick CAM angiogenesis 
model [366]. This angiogenesis is associated with 
induction of VEGF and angiopoietin-2 (Ang-2) mRNAs, 
and is inhibited by the angiogenesis inhibitors KDR-Fc 
(vs. VEGF) and Tie-2-Fc (vs. Ang-1 and Ang-2), as well 
as by inhibitors of the PAR1 signaling cascade, such as the 
protein kinase C inhibitor bisindolylmaleimide, the MAPK 
inhibitor PD980598, and the PI3K inhibitor LY294002 
[366]. Thrombin also promotes angiogenesis in tumor cells 
by activating VEGF production [165]. In endothelial cells, 
thrombin induces the expression of VEGFR2 [367] and the 
production of Ang-2 [368]. Thrombin also induces 
liberation of VEGF and Ang-1 in platelets [341, 342]. The 
PAR1 activation of angiogenesis is associated with up-
regulation of the growth-regulated oncogene-α (GRO-α) 
[369]. 
In the CAM angiogenesis model the 
PAR1antagonists SCH79797 and RWJ56110 have shown 
very potent antiangiogenic activity [370], which correlated 
with their inhibitory effect both in endothelial cell 
proliferation and DNA synthesis. This inhibitory effect 
was only evident when endothelial cells were at the fast-
growing state. However, when cells were in the quiescent 
state, the effect upon the DNA synthesis was much less 
evident. Both PAR1 antagonists also inhibited thrombin 
induced ERK1/2 activity in endothelial cells. This 
inhibition was specific for thrombin-mediated activation, 
as PAR1 antagonists did not have any effect on bFGF-, 
VEGF-, or EGF-induced ERK1/2 phosphorylation. 
Besides, the growth inhibition of endothelial cells by the 
PAR1 antagonists induced apoptosis, and this effect was 
due, at least in part, to caspase activation. The N-terminal 
peptide of PAR1 (1-41), which has been designated as 
“parstatin”, has shown potent angiogenesis inhibition 
[371-373], although its target receptor has not been 
identified. 
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7. MOLECULAR MAPPING OF PAR1 
ACTIVATION
The elucidation of the molecular mechanisms and 
structural points relevant for the protein/PAR1 interactions 
is crucial to ascertain the numerous cellular actions exerted 
via activation and signaling of PAR1. The master 
physiological regulator of PAR1 activation is thrombin 
and, in the last years, different works have been carried out 
to decipher the pivotal residues involved in 
thrombin/PAR1 interactions. The key residues of PAR1 
for interacting with thrombin are localized in six domains 
(Table 3), namely protease recognition site, tethered 
activating ligand, hirudin-like binding domain, ligand 
binding site 1, and the second and third extracellular loops. 
The relevance of each of these domains for the activation 
of PAR1 via thrombin is discussed in detailed in this 
section. Regarding the intracellular signaling exerted by 
PAR1, the scarce structural information has been 
commented above (Section 4). 
7.1. Protease recognition domain (PRS, L
38
DPR
41
) 
Initial site-directed mutagenesis studies revealed that 
the R41 residue is critical for receptor activation, 
suggesting that the information necessary for thrombin-
mediated PAR1 activation is afforded by the breakdown of 
the receptor at the R41-S42 peptide bond [1, 374]. Later, 
studies using a library of PAR1 N-terminus exodomains 
with single-amino acid alanine substitutions disclosed that 
L38 and P40 PAR1 residues are key for the adequate 
breakdown of PAR1 by thrombin, and indicated, by the 
first time, the essential role of L38 of PAR1 in the 
thrombin binding and cleavage [375]. Furthermore, 
modeling studies of PAR1/thrombin interaction supported 
this finding and indicated that the leucine L38 takes up the 
cavity shaped by the residues L99, I174 and W215 of 
thrombin [376]. The crystal structure of thrombin S195A 
bounded to an uncleaved extracellular PAR1 fragment 
confirmed the findings suggested in the modeling studies 
[377]. Besides, this crystal structure has also shown that 
the residue D39 of PAR1 binds to G216 and G219 of 
thrombin [377]. Additionally, the 3D structure showed that 
PAR1 P40 snugly fits into a hydrophobic pocket shaped by 
the residues Y60a, W60d, H57, and L99 of thrombin 
[377]. Regarding the PAR1 R41, this residue is implicated 
in widespread interactions with the thrombin F227, A190, 
E192, G219, S214, A195 and G193 residues. 
7.2. Tethered activating ligand domain (TAL, 
S
42
FLLRN
47
)
A loosely binding between R46 of PAR1 and E39 of 
thrombin was proposed by mutagenesis studies [376]. 
Besides, these studies also suggested the interaction 
between the amino acids P40, F43 and L45 of PAR1 and 
the amino acid S195 and H57 of thrombin. [376]. On the 
other hand, the crystal structure of thrombin bound to the 
uncleaved N-terminal extracellular fragment of PAR1 
showed important interactions between PAR1 S42 and 
thrombin L41 and K60f. The benzyl ring of PAR1 F43 
interacts with thrombin E192; PAR1 L44 stacks against 
thrombin L41;  PAR1 R46 interacts with the Q38 in the 
30-loop of thrombin; and PAR1 N47 makes a polar contact 
with the K149w in the autolysis loop of thrombin [377]. 
7.3. Hirudin-like binding domain (Hir, K
51
YEPF
55
)
This domain resembles the C-tail of the leech 
anticoagulant protein hirudin and it has been stablished 
that its presence is crucial for thrombin recognition [378]. 
Additionally, the interaction of this sequence with 
thrombin increases in an allosteric fashion the cleavage 
induced by thrombin [374, 376, 378].  Different studies 
have disclosed that the receptor residues Y52, E53, and 
F55 are crucial to establish specific interactions with 
thrombin. Especially, the residue Y52 appears to have a 
key role [17, 374, 379]. Receptor based peptides studies 
point out a bidentate interaction of PAR1 with thrombin. 
To evaluate this bidentate binding, Mathews et al. 
crystallized thrombin with the PAR1 sequence L38-E60, 
where the S42 residue had been mutated to Pro. [379]. 
Nevertheless, the bidentate interaction was not detected in 
a single crystal.  In its place, the L
38
DPR
41
 domain binds at 
the active site of one thrombin molecule in an unexpected 
nonproductive interaction, while, the K
51
YEPF
55
 domain 
of the same peptide engages at the fibrinogen recognition 
site of an additional thrombin molecule. This novel 
interaction between PAR1 peptides and thrombin seems to 
be related to the crystallization conditions [378]. The 
abovementioned 3D models of thrombin bound to PAR1 
identified a ionic interaction between the PAR1 amino acid 
E53, at the hirudin-like domain, and the thrombin amino 
acid R67 [376], in agreement with the data obtained from 
X-ray analysis [379] and the previous mutagenesis studies 
[380], which identified the residue R67 of thrombin as a 
crucial point of recognition. 
Crystal structures of the thrombin mutant D102N 
with the extracellular S42-N62 domain of PAR1 indicated 
that the binding of this PAR1 domain to the exosite I of 
thrombin triggers an important conformational change in 
thrombin as consequence of a long-range allosteric 
communication between the exosite I and the active site of 
this protease [381]. The N-terminal extracellular PAR1 
fragment interacts with the exosite I through polar and 
hydrophobic bonds, essentially in a similar conformation 
as commented above. 
Furthermore, for the first time, this crystal structure 
pointed out the crucial role of the PAR1 D50 residue in the 
PAR1/thrombin interaction. In addition, a crystal structure 
of thrombin bound to the uncleaved N-terminal 
extracellular fragment of PAR1 showed an interaction 
network for the hirudin-like binding domain of PAR1 
[377] in which the PAR1 Y52 interacts with the thrombin 
R73 and Q38; the PAR1 residue E53 is engaged by the 
side chain of the thrombin R75 and the backbone N of the 
Y76 in exosite I, also interacting with the T74 and R67 of 
thrombin. Finally, it was shown that the F55 of PAR1 has 
a weak π-cation interaction with the R67 residue of 
thrombin [377].
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Table 3. Key residues for thrombin/PAR1 binding drawn from structural studies 
Mutagenesisa X-Rayb NMRc
PAR1 domain PAR1 Thrombin PAR1 Thrombin PAR1
Protease recognition domain (L38DPR41)
L38 L99, I174, W215 L38 L99, I174, W215
D39 G216
P40 S195, H57 P40 Y60a, W60d, H57, L99
R41 F227, A190, E192, A195, S214, G219, G193
Tethered activating ligand domain 
(S42FLLRN47)
S42 L41, K60f
F43 S195, H57 F43 E192
L44 L41
L45 S195, H57 F43, L44, R46
R46 E39 R46 Q38
N47 K149w
Hirudin-like binding domain 
(D50KYEPF55)
D50 R73, K149 D50 R73, K149
Y52 Y52 R73, Q38 D50, K51
E53 R67 E53 R67, T74, R75,Y76
F55 I82, Y76 F55 R67, F34, I82
Ligand binding site domain 1(L84PAFIS89) F87 P85, A86, S89, I88
Second extracellular loop 
(Q242--------G265)
D256
E260
Third extracellular loop (A335------E350) E347
a References [1, 16, 169, 374-376, 378, 380, 382, 383]. b References [377, 379,381]. c NMR studies were carried out using a PAR1 A26-
Hse103 fragment.  Reference [17]. 
7.4. Ligand binding site domain 1 (LBS-1, L
84
PAFIS
89
)
This site is necessary for initiation of the transduction 
of signals. LBS-1 was identified by using a polyclonal 
antibody, anti-PAR
1-160
, which inhibited peptide ligand-
induced receptor activation in various cell types expressing 
PAR1 [382].  Furthermore, it was confirmed that this 
domain is an authentic ligand binding site in the full-length 
receptor [17].  
The NMR study of the PAR1 N-terminal exodomain 
identified, as a significant characteristic, the docking of the 
TAL domain onto the LBS-1 surface [17]. In this study, 
F43 and S89 display eight NOES, revealing a broad 
intramolecular interaction.  [17]. Besides, the PAR1 I88 
residue has hydrophobic intramolecular interactions with 
the L44 residue of thrombin An unexpected interaction 
was identified between P
85
-A
86
 and D
50
-K
51
peptide 
backbones, indicating that the length of the intramolecular 
ligand is greater than previously estimated. Notably, the 
TAL forms a tight turn in R46, whose guanidine group 
projects away from the LBS-1 [17]. 
7.5. Second and third extracellular loops (ECL2 and 
ECL3)
With the aim of identifying the domains or specific 
residues of PAR1 involved in its activation by PAR-APs 
or thrombin, Blackhart et al. carried out mutations on 
specific residues of ECL2 (D256A) and ECL3 (E347A) 
[16]. These mutations displayed deep changes on the 
functional responses of PAR1 to the PAR-APs or thrombin 
activation [16]. Furthermore, the substitution of D256 and 
E347 residues with asparagine and glutamine, respectively, 
pointed out the relevance of the negative charge of E347 in 
receptor activation, while the negative charge of the D256 
seems to be less critical. However, changes in amino acids 
involved in the response to synthetic peptides have little 
effect on the PAR1 activation by thrombin. Furthermore, 
these changes were capable of dissociating receptor 
specific agonist binding from functional activity.  This 
agonist-dependent selectivity of PAR1 binding could 
explain the agonist-based biased signaling commented in 
Section 4.1. This result has not been described for other 
GPCRs, pointing out that it may be an exceptional 
characteristic of receptors whose activation is mediated by 
a tethered ligand [16]. On the other hand, a potential role 
for an electrostatic interaction between R46 of the PAR1-
AP and E260 of ECL2 has been suggested [383].  
8. PAR1 MODULATORS
Considering that the activation of PAR1 triggers 
multiple physiological and pathophysiological effects, 
compounds able to interfere the PAR1/protein interactions, 
specifically PAR1/thrombin interactions, could be drug 
candidates to treat numerous disorders, such as those 
related to cardiovascular, immune, and nervous systems,
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inflammation and cancer. Additionally, PAR1-specific 
agonist and antagonists could be used as pharmacological 
tools to study their individual physiological functions. 
Nevertheless, the discovery of PAR1 modulators has been 
a demanding task because the intramolecular tethered 
ligand-binding mechanism is energetically favored. To 
overcome this matter, the key starting point was the 
structure-activity relationship (SAR) studies on diverse 
synthetic analogues of the tethered ligand capable of 
activating the receptor (PAR1-APs). In this sense, it is 
worth noting, the 14-mer peptide SFLLRNPNDKYEPF-
NH2, which resembles the 42-55 sequence of the N-
terminus of PAR1, and is a potent agonist for both 
thrombin receptor activation and platelet activation [1]. 
Deletions in the C- terminus of the 14-mer PAR1-AP 
guided the identification of the 6-mer SFLLRN-NH2 as the 
PAR1-AP with full agonist activity and the 5-mer SFLLR-
NH2 as the minimum sequence for this activity. [5, 384, 
385]. The structural requirements for PAR1/thrombin 
interactions have been delineated by extensive 
modifications of these PAR1 activating peptides, which 
have delineated the basis for antagonists rational design.. 
In this regard, the SAR studies in the 5-mer PAR1-AP 
have allowed the identification of the Phe, Leu and Arg 
side chains as key points, along with the need of the free 
N-terminal amine [384-390]. These and other 
modifications, including the incorporation of heterocyclic 
and macrocyclic moieties into the PAR1-APs, have 
provided several peptide PAR1 ligands with agonist, 
antagonist and mixed agonist-antagonist activity, but often 
with low potency and selectivity [21, 391]. The peptide 
TFRRRLSRATR derived from the C-terminal sequence of 
the human platelet P2Y1 receptor has been characterized 
as a peptide PAR1 agonist in which the pentapeptide 
TFRRRL is the minimum fragment able to directly 
activate human platelets through the PAR1 receptor [58]. 
Various pharmaceutical companies have dedicated 
efforts to provide powerful and selective PAR1 antagonists 
with therapeutic application, especially in the thrombosis 
and atherosclerosis/restenosis field [21, 392, 393]. In this 
sense, a rational design of peptidomimetics and a random 
high throughput screening (HTS) of small-molecules were 
chosen as strategies.  
The rational design strategy led to a family of potent 
PAR1 antagonists by modification of the most potent 5-
mer peptide with full agonist activity, SF(f)F(Gn)LR- NH2
(f = p-fluoro;Gn = p-guanidino). The substitution of the 
serine residue by a trans- cynnamoyl or phenylpropynoyl 
moiety, along with the incorporation of basic residues at 
the C-terminus, gave rise to the identification of BMS-
200261 (1) as the most potent antagonist of the 
synthesized analogues [394] (Fig. 3). This derivative was a 
selective PAR1 antagonist relative to PAR-2 [122] and 
PAR-4 [395, 396]. 
Fig. (3). PAR1 antagonists obtained following a rational design.
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The de novo design of PAR1 peptidomimetic 
antagonists was a successful strategy to obtain potent 
PAR1 antagonists. Hence, based on the widespread SAR 
knowledge on PAR1-APs and the 5-mer peptide as the 
minimum sequence necessary for the full agonist activity, 
the Maryanoff group from Johnson and Johnson defined a 
“three-point model”, in which the N-terminal amine, the 
benzene ring of the Phe residue and the central carbon of 
the Arg guanidine moiety were the key residues [385, 393] 
(Fig. 3). In accordance with the peptidomimetic definition, 
this pharmacophore model was combined with rigid 
scaffolds to obtain several PAR1 antagonists [21, 392, 
393]. Therefore, the 6- aminoindole moiety was initially 
chosen as scaffold to suitably orient the three key 
functional groups of SFLLR providing a first series of 
PAR1 antagonists. In an attempt to avoid undesirable 
cardiovascular effects, these series were further optimized, 
by replacing the guanidine moiety, leading to the 
compound RWJ-56110 (2) (Fig. 3). The antagonist 
potency, PAR1 selectivity, lack of cytotoxicity, and 
minimal effect on collagen-induced platelet aggregation 
showed by RWJ-56110, made this compound attractive to 
carry out further biological evaluations [370, 397-399]. 
The first results showed by RWJ-56110 prompted the idea 
that PAR1 could be an important target to develop 
antiangiogenic drugs for cancer and other angiogenesis-
related diseases. However, RWJ-56110 showed 
hypotensive effects therefore, with the aim to improve the 
cardiovascular safety profile of the indole-based 
peptidomimetics, the indole template was substituted by 
the bioisostere indazole moiety. From this new series, a 
potent and selective indazole-based PAR1 antagonist 
named RWJ-58259 (3) was found [397]. Furthermore, 
RWJ-58259 is used as a standard reference in 
pharmacological evaluations. [400]. This derivative 
displayed protection against thrombus formation in 
nonhuman primates giving the earliest in vivo evidence to 
support the potential clinical benefit of PAR1 antagonists 
in humans [401, 402].  
Additional changes in the template of 
peptidomimetics based on an indole scaffold comprise the 
introduction of a 2-methyl group into the 5- and 6- 
aminoindole scaffold and the substitution of this 
heterocyclic skeleton with the 1,4-benzodiazepine 
privileged scaffold [403] or different small bifunctional 
templates (piperidine, azetidine, cyclohexane and indole) 
[404]. The capacity of these derivatives to suppress 
SFLLRN-NH2 induced platelet aggregation- and thrombin-
mediated calcium signaling was moderated. Additionally, 
the synthesis of diverse small directed libraries of different 
scaffolds able to assemble, at least, one or two aromatic 
groups and one or two basic groups at variable distances 
and orientation have recently been described, as well as 
their evaluation as human PAR1 antagonists in a platelet 
aggregation assay and as cytotoxic agents in human cancer 
cell lines [405-408]. Some of the compounds displayed 
moderate PAR1 antagonist activity, while, others were 
cytotoxic at µM concentration. No correlation was 
observed between both types of activities.  
Moreover, different researches have provided 
numerous series of structurally diverse potent 
PAR1antagonists found by HTS of combinatorial libraries 
of non-peptide small molecules followed by optimization. 
Representative molecules obtaining following this strategy 
are summarize in Fig. 4 and reviewed below.   
The first non-peptide PAR1 antagonists described 
was the 1,3-thiazolidinone derivative named FR171113 
(4). This compound, discovered by Kato et al. from 
Fujisawa Pharmaceutical as specific antagonist of PAR1, 
inhibited arterial thrombosis in guinea pigs inhibit arterial 
thrombosis in guinea pigs [409, 410]. 
Barrow et al. from Merck first identified a tris-urea 
analogue with PAR1 antagonist activity, which was 
structurally modified and optimized to obtain more potent 
mono-ureas, such as 5 (Fig. 4) [411]. Additionally, 
directed screening followed by lead optimization provided 
a second family of non-peptide PAR1 antagonists, 
exemplified by the phenylisoxazole derivative 6 [412]. The 
IC50 values of these two compounds, in the PAR1 
radioligand binding assay and in a [
3
H] serotonin assay, 
were in the submicromolar range.. 
The next series of thrombin receptor antagonists were 
four series of compounds patented by Eisai Company 
[413-415]. Among them, E-5555 (7) showed the most 
promising profile and oral bioavailability. This compound 
is an emerging oral antithrombotic drug that is undergoing 
Phase II clinical trials for coronary artery disease in 
Japanese population [416]. Nevertheless, scarce preclinical 
data on this drug have been reported [21].
Researches from Schering Plough, first, described the 
pyrroloquinazoline SCH-79797 (8) and its N-methyl 
analogue SCH-203099 (9) as potent and selective PAR1 
antagonists in human platelets and human coronary artery 
SMCs [417, 418]. SCH-79797 and the previously 
commented RWJ-56110, are the only two PAR1 
antagonists that have showed potent antiangiogenic 
activity in in vivo models [370, 399]. Besides, the Schering 
Plough derivative displayed antiproliferative activity, 
inhibited cell migration and reduced myocardial ischemia-
reperfusion injury [128, 419, 420]. Moreover, SCH-79797 
inhibited the growth of different human and mouse cell 
lines, although this antiproliferative activity is likely not 
related to PAR1 antagonism [421].
The same pharmaceutical company developed a 
fruitful and unexpected family of non-peptide PAR1 
antagonist based on the central scaffold of the natural 
product himbacine. In a HTS campaign focused on the 
search of muscarinic receptor ligands, it was found an 
himbacine derivative containing a pyridine ring that later 
was identified as a selective PAR1 antagonist vs 
muscarinic receptor [392, 422]. Extensive structural 
modifications on the pyridine ring, the himbacine tricycle 
moiety and the stereochemistry allowed the identification 
of SCH-530348 (10), called vorapaxar [21]. This 
himbacine analogue exhibits excellent oral bioavailability 
and is currently undergoing Phase III clinical trials in 
patients with acute coronary syndrome and in patients with 
atherosclerosis [423-426]. 
In 2012, the crystal structure of vorapaxar (10) bound 
to human PAR1 was obtained, opening new avenues to the 
design of improved PAR1 antagonist [427]. Vorapaxar 
binds to PAR1 in a region very close to the extracellular 
surface of PAR1 showing an unusual mode of drug 
binding, in which vorapaxar is surrounded by residues 
from TM3, TM4, TM5, TM6 and TM7, as well as ECL2 
and ECL3, shielding this antagonist from the solvent 
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[427]. This structure is a good example of the irreversible 
binding of a small molecule to inhibit receptor activation 
by the tethered ligand of PAR1 and provides a model, as a 
starting point, for the development of PAR1 antagonists. In 
this sense, this model has been used to guide and explain 
the structure-activity relationships of a series of spirocyclic 
analogues of vorapaxar (11) that showed activity and rat 
plasma levels comparable to vorapaxar [428]. Based on the 
crystal structure of the complex vorapaxar-PAR1, a recent 
virtual screening study, aimed to identify phytochemicals 
with antagonist activity against PAR1, has been carried 
out. This study has led to the identification of 
phytochemicals as PAR1 antagonists, which showed 
interaction with, at least, one residue of the vorapaxar 
binding site. Nevertheless, further experimental studies are 
necessary to validate their antagonistic activity against 
PAR1 [429]. 
Fig. (4). Non-peptide PAR1 antagonists
On the other hand, the tricyclic ring of vorapaxar was 
substituted by an octahydroindene core, providing PAR1 
antagonists with comparable potency to vorapaxar, 
although these compounds were not metabolically stable in 
human and mouse liver microsomes [430].  
In a search for novel structures, Pierre Fabre 
laboratories carried out a HTS campaign and described 
two new series of PAR1 antagonists not structurally 
related, among them the imidazole derivative 12 [431] and 
the piperazine-derived amides, represented by 13 (F 
16618) [432, 433] were selected. The last one, the most 
advanced PAR1 antagonist of these series, has shown 
potent antithrombotic activity in vivo and a reduction of 
the restenosis in the carotid artery of rats without affecting 
clotting time [434-436]. 
The modulation of PAR1 activation in an allosteric 
fashion opens new ways to obtain PAR1 modulators with 
an improved therapeutic window and increased selectivity. 
However, up to now, this approach has been poorly 
investigated and only three examples have been described 
following this approach (Fig. 5) [100, 101, 437]. Thus, the 
screening of a small-molecule library for inhibitors of 
platelet activation led to a new family of molecules, which, 
by binding to the PAR1 8
th
 helix, modify PAR1-mediated 
granule secretion [100]. Among them, the quinoline 
derivative 14 was identified as a potent allosteric PAR1 
antagonist. This antagonist was inactive in a PAR1 mutant, 
where the 8
th
 helix was deleted, supporting the important 
role of this helix for activity. Evaluation of downstream 
signaling showed that 14 was selective with regard to G 
protein coupling, blocking signaling mediated by Gαq but 
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not by Gα12. Later, Astereti et al. identified two 
benzimidazole derivatives (15, 16) as selective negative 
modulators of PAR1 Gαq signaling and positive allosteric 
agonists of PAR1 Gαi signaling [437]. Finally, from a HTS 
of the National Institute of Health Molecular Libraries 
Small Molecule Repository (NIH-MLSMR) and further 
optimization, the 1,3-diaminobenzene 17 was described as 
an allosteric antagonist of PAR1. This compound inhibited 
platelet aggregation induced by a PAR1 peptide agonist or 
by thrombin but not by several other platelet agonists 
[101].
Fig. (5). Allosteric PAR1 modulators.
Apart from the aforementioned PAR1 inhibitors, a 
new strategy to obtain PAR1 antagonist based on lipidated 
cell-permeable peptides, which mimic intracellular loop 
sequences, has shown promising effects in the prevention 
of blood clotting and in animal models of breast cancer  
[438, 439]. These antagonists, named pepducins, interfere 
with PAR1/G protein binding on the inside surface of the 
receptor, in contrast to classical ligands [105, 440]. The 
design of pepducins was carried out on the basis of the 
mutagenesis studies that allowed identifying that the third 
intracellular loop (i3) of a GPCR is responsible of the 
coupling between the receptor and its corresponding G-
protein [441]. Furthermore, the i3 domain based 
pepducins, which contains intracellular residues from the 
adjacent TM5 of PAR1, provoked a fast intracellular 
calcium influx rather than the inhibition of platelet 
activation [105, 440]. From these findings, succeeding 
shortening and N-palmitoylation yielded P1pal-
12pepducin (Palmitoyl-NH-RCLSSSAVANRS-NH2), as a 
full PAR1 antagonist, capable of preventing SFLLRN-
NH2-induced platelet aggregation and blocking thrombin-
induced calcium response [105, 440]. This pepducin
together with the smaller heptapeptide derivative P1pal-7 
(Palmitoyl-NH-KKSRALF-NH2), also a full antagonist, 
reduced in a significant way the tumor growth and the 
angiogenesis of breast cancer xenografts in nude 
mice[442] and in primary lung cancer cells [443].
Apart from the aforementioned PAR1 inhibitors, a 
new strategy to obtain PAR1 antagonist based on lipidated 
cell-permeable peptides, which mimic intracellular loop 
sequences, has shown promising effects in the prevention 
of blood clotting and in animal models of breast cancer  
[438, 439]. These antagonists, named pepducins, interfere 
with PAR1/G protein binding on the inside surface of the 
receptor, in contrast to classical ligands [105, 440]. The 
design of pepducins was carried out on the basis of the 
mutagenesis studies that allowed identifying that the third 
intracellular loop (i3) of a GPCR is responsible of the 
coupling between the receptor and its corresponding G-
protein [441]. Furthermore, the i3 domain based 
pepducins, which contains intracellular residues from the 
adjacent TM5 of PAR1, provoked a fast intracellular 
calcium influx rather than the inhibition of platelet 
activation [105, 440]. From these findings, succeeding 
shortening and N-palmitoylation yielded P1pal-
12pepducin (Palmitoyl-NH-RCLSSSAVANRS-NH2), as a 
full PAR1 antagonist, capable of preventing SFLLRN-
NH2-induced platelet aggregation and blocking thrombin-
induced calcium response [105, 440]. This pepducin
together with the smaller heptapeptide derivative P1pal-7 
(Palmitoyl-NH-KKSRALF-NH2), also a full antagonist, 
reduced in a significant way the tumor growth and the 
angiogenesis of breast cancer xenografts in nude 
mice[442] and in primary lung cancer cells [443].
9. CONCLUSIONS AND PERSPECTIVES 
The plethora of clinical and experimental evidences 
that associate PAR1 expression and activation with diverse 
disease conditions strongly supports the interest of this 
receptor as a promising therapeutic target. However, there 
are several challenges that should be resolved before 
considering PAR1 a validated drug target. (a) Targeting 
PAR1 and developing PAR1-targeted therapeutic agents, 
particularly to the CNS, represents a substantial hurdle, 
due to its bimodal actions (inflammatory/anti-
inflammatory; relaxation/contraction; endothelial barrier 
disruption/stabilization; neuronal damage/protection; 
neurodegeneration/neuroprotection), depending on the 
protease agonist, the agonist concentration, the cell-, 
animal species-, and disease stage-expression specificity, 
which are still poorly understood. (b) Due to the animal 
species specific PAR1 expression, the development of a 
humanized mice model is urgently needed for in vivo
assays, to avoid the use of primates in the first preclinical 
studies. (c) In spite of the advances in the last years in the 
knowledge of the complex network of the PAR1 
interactome, fundamental questions regarding the 
mechanisms that control signaling selectivity in this multi-
liganded and multi-functional receptor wait for an answer 
and further research is needed to fully fathom the 
molecular basis of the role of PAR1 in pathology and of its 
pharmacological control. (d) Structural studies to 
determine the binding sites of agonists and antagonists at 
PAR1 are necessary for a structure-based design of more 
potent and selective PAR1 modulators. In this point, it is 
noteworthy the recent report on the X-ray structure of the 
complex of PAR1 with its antagonist vorapaxar [427], as 
well as, the reports on the G protein selective allosteric 
antagonists [100, 101, 437]. These reports open the door to 
the structure-based design of selective and potent PAR1 
modulators as invaluable pharmacological tools to better 
unravel the PAR1 interactome and validate it as 
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therapeutic target and as drugs in a near future. Taking into 
account that PAR1 not only signals through G protein, the 
signaling studies should not be limit to those based on G 
protein second messengers that would miss other signaling 
pathways.    
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ABBREVIATIONS 
AC = Adenylate Cyclase 
ACS  = Acute Coronary Syndromes  
ALI  = Acute Lung Injury  
ALK V  = Activin-Like Kinase V 
ALS = Amyotrophic Lateral Sclerosis 
c-AMP = cyclic Adenosine Monophosphate 
Ang-2 = angiopoietin-2 
AP-2 = Clathrin adaptor Protein complex 2
APC =  Activated Protein C 
ARE = Androgen Response Elements 
BBB = Blood-Brain Barrier 
bFGF = basic Fibroblast Growth Factor 
BicD1 = Bicaudal D1 
CAM = ChorioAllantoic Membrane 
CB1 = Cannabinoid receptor 1 
CCL2 = Cc Chemokine Ligand 2 
CINCs = Cytokine-Induced Neutrophil 
Chemoattractants 
CK2 = Casein Kinase 2 
CNS = Central Nervous System 
CTGF = Connective Tissue Growth Factor 
DAG = Diacylglycerol 
DVT = Deep Vein Thrombosis 
ECL2 = Extracellular Loop 2 
ECs  = Endothelial Cells 
EGR-1 = Early Growth Response-1 
ELISA = Enzyme-Linked Immunosorbent Assay 
eNOS  = endothelial Nitric Oxide Synthase 
EPCR = Endothelial Protein C Receptor 
ERK = Extracellular Regulated Kinase 
Etk/Bmx = Bone marrow tyrosine kinase in 
chromosome X 
FAK = Focal Adhesion Kinase 
FVIIa = Factor VIIa 
FXa = Factor Xa 
FRET = Fluorescence Resonance Energy Transfer 
GDP = Guanosine Diphosphate 
GEFs = Guanine-nucleotide Exchange Factors 
GI  = Gastrointestinal 
GPIIb/IIIa = Glycoprotein IIb/IIIa 
GPCRs = G-Protein Coupled Receptors 
GRK = G protein Receptor Kinase 
GRO-α = Growth-Regulated Oncogene-α
GSK =  Glycogen Synthase Kinase 
GTP = Guanosine Triphosphate 
hCASMC = Human Coronary Artery Smooth Muscle 
Cells
HER2 = Human Epidermal growth factor Receptor 2 
HGF = Hepatocyte Growth Factor 
HMVEC = Human Microvessel Endothelial Cells 
HIF-1 = Hypoxia-Inducible Factor 1-
HIV = Human Immunodeficiency Virus  
hMCs  = human Mast Cells 
Hsp = Heat shock protein 
HUVECs  = Human Umbilical Vein Endothelial Cells 
i = intracellular loop (1-3) 
IBD  = Inflammatory Bowel Diseases 
IBS  = Irritable Bowel Syndrome  
ICU = Intensive Care Unit  
IGFR  = Insulin-Like Growth Factor Receptor  
IP3 = Phosphoinositide 
IL = Interleukin 
Ki = Potassium Channels 
KLK = Kallikrein-Related Peptidases 
LBS = Ligand Binding Site 
LMWH = Low-Molecular Weight Heparin 
LPA = LysoPhosphatidic Acid 
LPS  = Lipopolysaccharide 
LTP = Long Term Potentiation 
LV  = Left Ventricular 
MAPKs = Mitogen-Activated Protein Kinases  
MCP-1 = Monocyte Chemoattractant Protein-1 
MEK = Mitogen-activated protein kinase Kinase 
MI  = Myocardial Infarction 
MIF  = Macrophage migration Inhibitory Factor 
MMP-1 = Matrix Metalloprotease-1 
MMP-13 = Matrix Metalloprotease-13 
MS = Multiple Sclerosis 
MT-SP1 = Membrane-Type-Serine Protease 1 
NADPH = Nicotinamide Adenine Dinucleotide 
Phosphate 
NE = Neutrophil Elastase 
NMDA = N-Methyl-D-Aspartate 
NMR = Nuclear Magnetic Resonance 
NOE = Nuclear Overhauser Effect 
NOS = Nitric Oxide Synthase 
PAD  = Peripheral Artery Disease 
PARs =  Protease-Activated Receptors 
PAR-APs = PAR-Activating Peptides 
PDGF = Platelet-Derived Growth Factor 
PDGFR  = Platelet-Derived Growth Factor Receptor 
PE = Pulmonary Embolism 
PGE2 = Prostaglandin E2 
PHB  = Prohibitin 
PI3K = Phosphatidylinositol-3-Kinase 
PKC = Protein Kinase C 
PLCβ = Phospholipase Cβ
PR3 = Neutrophil Protease-3 
PRS  = Protease Recognition Sequence 
PTX = Pertussis Toxin 
RANTES = Regulated on Activation Normal T cell 
Expressed and Secreted 
RGS  = Regulator of G-protein Signalling 
RNA = Ribonucleic Acid 
mRNA = messenger Ribonucleic Acid 
ROCK = Rho-Kinase 
ROS = Reactive Oxygen Species 
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RSTKs  = Receptor Serine/Threonine Kinases 
RTKs  = Receptor Tyrosine Kinases  
SAR = Structure-Activity Relationships 
Shc = Src homology and collagen protein 
siRNA = small interfering RNA 
SMCs = Smooth Muscle Cells 
SNX1 = Sorting Nexin 1 
S1PR  = Sphingosine 1-Phosphate Receptors 
SRE = Serum Response Elements 
TAL = Tethered Activating Ligand 
TβRI  = Transforming growth factor Beta Receptor  
TF = Tissue Factor 
TGF-α = Transforming Growth Factor-α
TK = Tyrosine Kinase 
TNF = Tumor Necrosis Factor 
Tpl2 = Tumor progression locus 2  
TRPV  = Transient Receptor Potential Vanilloid ion 
channel 
VEGF = Vascular Endothelial Growth Factor 
VEGFR2 = Vascular Endothelial Growth Factor 
 Receptor 2 
VSMCs  = Vascular Smooth Muscle Cells 
VTE = Venus Thromboembolism 
vWF  = von Willebrand Factor 
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